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                                                                     ABSTRACT  
         BACKGROUND: Cardiovascular disease is the leading cause of death in the 
world. The mortality rate due to cardiovascular risk is six times more pronounced in 
individuals with diabetes mellitus than in others. So we have to diagnose the 
cardiovascular risk at an earlier date to prevent the onset of complications. AIMS 
AND ABJECTIVES: (i) To find the correlation between total leucocyte count, 
microalbuminuria and cardiovascular risk in type 2 diabetes mellitus. (ii) to evaluate 
other risk factors of diabetes like increased BMI, waist circumference, family history, 
and smoking with microalbuminuria, leucocyte count and cardiovascular risk. 
MATERIALS AND METHODS: After getting institutional ethical commitee200 
diabetic individuals of both men and women between ages 35-55 years were selected. 
Exclusion criteria includes type 1 diabetes mellitus, known malignant disease, after 
vigorous exercise, history of heart disease, urinary tract infection, liver cirrhosis, 
haematological diseases, advanced renal dysfunction(serum creatinine >2.0mg/dl), 
those taking medications like steroid and anti allergy  agents. Parameters like blood 
pressure, waist circumference, BMI, total leucocyte count, fasting blood sugar, 
HbA1C, urine for microalbuminuria and ECG changes were recorded in a master chart 
in two groups microalbuminuria group and normoalbuminuria group.  Results 
analysed using mean, standard deviation, correlation was calculated using spearman 
rho correlation. RESULTS: The prevalence of microalbuminuria was 33%, increased 
leucocyte count was found 27%, and ECG changes were found in 24%.  There is a 
significant correlation between microalbuminuria, total leucocyte count. 
Microalbuminuria was associated with increased blood pressure, smoking, HbA1C, 
fasting blood sugar. CONCLUSION: Since there exists a correlation between total 
leucocyte count, microalbuminuria, and cardiovascular risk, total leucocyte count can 
also be used as a simple and cost effective method to detect the microvascular and 
macrovascular complications earlier thereby reducing the mortality and morbidity 
associated with complications.   
Key words: Type 2 diabetes mellitus, microalbuminuria, total leucocyte count, 
cardiovascular risk                                     
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INTRODUCTION 
         Cardiovascular disease is the leading cause of mortality in the world. 
According to WHO 2012, nearly 17.5 million deaths per year are due to this 
condition
1
. Now in developing countries cardiovascular disease has become a 
major health concern in the middle age population and the cardiovascular 
mortality is much more than in developed countries. This result in the 
economic burden of the family due to loss of productivity of working 
individuals and these cardiovascular changes are more pronounced in 
individuals with diabetes mellitus than in others. 
In 1997, the American diabetes association defined diabetes as “a 
group of metabolic disorders characterized by hyperglycemia resulting from 
defects in insulin secretion, insulin action or both. WHO modified this 
definition as “a metabolic cum vascular syndrome of multiple etiology 
characterised by chronic hyperglycemia with disturbance of carbohydrate, fat 
and protein metabolism resulting from defects in insulin secretion, insulin 
action or both leading to changes in small blood vessels (Microangiopathy) and 
large blood vessels (macroangiopathy)”.Two types of diabetes mellitus have 
been identified type 1 and type 2 diabetes mellitus. Among them 90% is type 2 
diabetes and it is underway increasing both in developed and developing 
countries
2
. 
Globally the prevalence of diabetes is expected to arise from 220 million 
in 2010 to 300 million in 2025 and each diabetic individual will spend about 
three times greater on their health compared to a person without diabetes
3
. 
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Type 2 diabetes mellitus is a chronic progressive disease associated with long 
term devastating complications which can be fatal and becoming one of the 
world‟s most important non communicable diseases. It is known to occur in 
genetically predisposed persons, exposed to environmental influences that 
precipitate the onset of clinical disease. Diabetes can be differentiated into 
monogenic and polygenic forms based on clinical grounds and in terms of 
genes involved in the pathogenesis of this disorder
4
. Risk factors include age, 
sex, and ethnic background etc. 
Epidemiological determinants and risk factors of type 2 diabetes include 
family history, genetic markers, thrifty genes and demographical characters 
like sex, age, ethnicity, behaviour and life style related risk factors like obesity, 
physical inactivity, diet, stress, westernisation, urbanisation and 
modernisation
5
. This metabolic disorder results from insulin resistance 
resulting in various pathophysiological changes in body organs. Previous 
thought was that children and young adults were affected by type 1 diabetes 
and type 2 diabetes occurs in middle aged individuals. But this has started 
changing now because of increased prevalence of diabetes. 
As the age of onset of diabetes has decreased and average lifespan of an 
individual has increased, they are more prone to develop complications and 
have to live longer with complications.
6
 Most of the morbidity and mortality of 
diabetes is due to the chronic complications of the disease. The chronic 
complications of diabetes are due to pathological changes affecting blood 
vessels of the involved organs. The disease can involve either small blood 
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vessels or larger blood vessels. Diabetic retinopathy and nephropathy are 
predominantly microvascular diseases and cardiovascular disease occurs due to 
macrovascular changes. 
These complications can be reduced by educating the patient about the 
disease, its complications and by regular follow up investigations. Poor 
glycemic control that result in long term complications leads to morbidity, 
mortality and economic burden of the disease. 
          The basic pathology of macrovascular disease is atherosclerosis. Risk 
factors for atherosclerosis in diabetes mellitus include hyperglycemia, 
hyperlipidemia, hypertension, cigarette smoking, and positive family history of 
diabetes
7
. There is an increasing evidence of association between fasting blood 
glucose and risk of macrovascular complications.  
Cardiovascular complications are increased by two fold to six fold in 
individuals with diabetes. The mortality rate is increased in diabetic individuals 
than normal persons because of diabetic complications. There is a continuous 
relationship between level of glycemia and risk of development of these 
complications. Hyperglycemia and insulin resistance appears to play an 
important   role in the development of complications. 
Peripheral leucocyte count is associated with insulin resistance, type 2 
diabetes, coronary vascular disease, stroke and diabetes related micro and 
macrovascular disease. There are studies indicating that an elevated WBC 
count even within the normal range is associated with complications in type 2 
diabetes. An association between leucocyte count and coronary artery disease 
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has been observed after adjusting for multiple risk factors of coronary heart 
disease including smoking
8
.  
And there is upcoming evidence that leucocyte count, fibrinogen   and  
C-reactive protein are all positively correlated with atherosclerosis 
accompanied by inflammation. There have been only few researches on the 
relation between vascular complications and leucocyte count. Although studies 
are available for relation between microalbuminuria and cardiovascular disease 
as microalbuminuria is now seen as a sign of generalised endothelial 
dysfunction and large prospective studies have shown a strong correlation 
between glycemic control and microvascular complications
9
. Our chief role is 
therefore to detect these complications at an earlier stage to avoid the 
progression to irreversible stage. 
So we need a cost effective and benefit method to identify those type 2 
diabetic patients who need care and attention. Total leucocyte count is such a 
cost effective and easily available laboratory investigation that shows the 
overall inflammatory activity occurring in the body. Therefore we carried out a 
cross sectional study to correlate the relation between  total leucocyte count, a 
biomarker of inflammation, and microalbuminuria a sign of endothelial 
dysfunction with cardiovascular risk factors among type 2 diabetes mellitus 
individuals for a better prognosis. 
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AIMS AND OBJECTIVES 
 
1. To find the correlation between total leucocyte count and 
microalbuminuria. 
2. To find the correlation between differential count and microalbuminuria. 
3. To find the association between total leucocyte count and cardiovascular 
risk. 
4. To evaluate the relationship between total leucocyte count, differential 
count, microalbuminuria and cardiovascular risk factors. 
5. To evaluate the other risk factors of diabetes like increased BMI, waist 
circumference, family history, and smoking with microalbuminuria, 
leucocyte count and cardiovascular risk. 
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REVIEW OF LITERATURE 
 
HISTORY OF DIABETES 
 
 In the 2nd century A.D, Roman physician Aretaeus used diabetes which 
means “to pass through”.  In 400-500 B.C, charaka and sushruta differentiated 
diabetes mellitus from diabetes inspidus. They recognised two types of 
diabetes, lean diabetes (type 1) and obese diabetes (type 2). They noted that 
diabetes runs in families and described polyuria and glycosuria (honeylike 
urine).
10
 
In 1869, Paul Lagerhans from Germany discovered two systems of 
cells present in the pancreas. One set of cells secrete normal pancreatic juice, 
and the other set of cells are identified as „Islets of Langerhans ‟. In 1901, 
Eugene Opie mentioned „Diabetes mellitus‟ is due to Islets of Langerhans 
destruction partly or totally. 
  In 1920 Frederick G. Banting, an orthopaedic surgeon employed as a 
lecturer in physiology while preparing for the lecture thought a way to extract a 
substance from pancreas that can be used to reduce blood sugar level. He and 
his assistant a medical student Charles H. Best induced diabetes in dogs by 
removing the pancreas and tried to see whether glycosuria could be suppressed 
by administration of fluid isolated from Islet of Langerhans of other healthy 
dogs. In July 1921, first positive result came. Dog Marjorie was kept alive with 
pancreatic extract injections for 70 days. The extract named Isletin was 
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extracted in pure form with a technical guidance of Macleod and the help of 
expert biochemist J.B. Collip. In 1923 Nobel Prize in medicine was awarded to 
Banting and   Macleod
11
. 
 
EPIDEMIOLOGY OF DIABETES MELLITUS 
Diabetes mellitus is the most common metabolic disorder in the world. 
According to IDF 382 million people in the world live with diabetes as of 
2013. The number of individuals with diabetes is increasing steadily in most 
countries.  
China has the largest number of diabetic individuals in the world (92 
million), followed by India with 65.2 million
12
 
 
In the year 1971 at the time of first national survey the prevalence rate 
was 2.3%in the urban areas and 1.2% in the rural areas. Now the prevalence 
was 15-20%in the urban areas and half of that in rural areas. India is currently 
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in the grip of an explosive epidemic of type 2 diabetes. As per the latest 
statistics, we have more than 60 million people living with diabetes in India 
and it is even worrying that more than 50% of individuals with diabetes remain 
unaware that they have this condition.  
Type 2 diabetes mellitus comprises 85-95% of all cases of diabetes, type 
1 diabetes contributes around 5% and other forms of diabetes are rare. There is 
an explosive increase in prevalence of type 2 diabetes in developing countries 
and steady increase in prevalence of type 2 diabetes in developed countries. 
The explosive increase in the prevalence of diabetes is due to the 
modernisation, urbanisation, and industrialisation leading to overweight and 
obesity in a genetically predisposed individual.  
 Type 2 diabetes is a disease of late middle age and occurs a decade 
earlier in India than in west and even in non-obese individuals. Self reported is 
39.1%, undiagnosed is 60.9%, 25% of individuals have never heard of diabetes, 
60% do not know that diabetes can lead to organ complications, more than 80% 
do not know the risk factors for diabetes, 60% do not know that diabetes can be 
prevented and 50% have poor glycemic control
13
. 
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TYPE 2 DIABETES MELLITUS 
 
NORMAL GLUCOSE METABOLISM 
Dietary carbohydrates are the main source of energy. Major 
carbohydrates in diet are starch, glycogen, sucrose, lactose, fructose and 
cellulose. Complex carbohydrates are broken down into monosaccharides and 
then absorbed. The metabolic fate of glucose is determined whether the 
individual is in fasting or in the fed state. In the fed stage various biochemical 
processes are attuned towards energy storage. In the fasted state the process are 
directed towards breaking the energy depots and ensuring constant supply of 
glucose to the brain and of other metabolic fuels to the other tissues. The main 
storage form of glucose in animals is glycogen. Glycogen is a complex 
carbohydrate consisting of repeated units of glucose and found chiefly in the 
liver and skeletal muscles. 
In the skeletal muscle it occurs as a readily available source of energy 
during muscle contraction, whereas in liver it contributes to the hepatic glucose 
output during fasting. Large amounts of lactate are generated during muscle 
contraction by means of anaerobic glycolysis. This lactate thus generated is 
transported to liver where it is reconverted to pyruvate and then to glucose. 
This process is a gluconeogenic mechanism and the blood sugar is kept 
constant even during strenuous physical activity. The lactate cycle is known as  
Cori’s cycle.  
10 
 
Other substrates for gluconeogenesis include the glucogenic amino acid 
alanine and the glycerol part of neutral fat.  In addition to liver, kidney is 
another major site for gluconeogenesis. However liver is the only organ where 
free glucose can be released into systemic circulation.  
 
HORMONAL CONTROL OF GLUCOSE 
For optimal functioning of all organs especially the brain, it is essential 
to maintain the blood glucose within a normal range. This requires the            
coordinated actions of various hormones acting together. Insulin is the only 
hormone which brings down the blood glucose level. Arrayed against it are a 
group of molecules commonly termed “counter- regulatory hormones”. 
 
Insulin Decrease Blood Glucose 
  
 
 
By Promoting 
 
By Inhibiting 
 
Glycogenesis    
Lipogenesis   
Protein synthesis                           
 
Gluconeogenesis 
Glycogenolysis 
Protein breakdown 
Lipolysis 
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Increased blood glucose (counter regulatory hormones) 
 Glucagon promotes glycogenolysis 
 Glucocorticoids promotes gluconeogenesis 
 Growth hormone and catecholamines promote glycogenolysis and 
gluconeogenesis. 
 
In the fed state insulin promotes the glucose utilising and energy storing 
process (glycogen synthesis, fat synthesis (triglyceride), protein synthesis) and 
inhibits glucose producing process (glycogenolysis and gluconeogenesis) and 
lipolysis. In the fast state, the blood sugar levels are maintained by combination 
of inhibition of insulin release and increased action of counter -regulatory 
hormones.
14 
 
INSULIN        
Insulin a polypeptide hormone is secreted by the beta cells of islets of 
langerhans of pancreas. Insulin is synthesised from its precursor 
preproinsulin, which gets broken down to proinsulin which in turn is cleaved 
to form equimolar concentration of insulin and C-peptide or connecting 
peptide. Insulin is thus stored in secretory vesicles in the cytoplasm of beta 
cells.  
  
 
 
 
STRUCTURE OF INSULIN 
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When the individual is replete with glucose, e.g. after a meal, glucose 
enters the beta cell through glucose transporter-2 (GLUT-2), an insulin 
independent transporter. Adenosine tri phosphate is formed to yield energy 
when glucose is metabolised by the enzyme glucokinase. 
High level of ATP in the cell lead to closure of a special transporter 
on the cell membrane called K-ATP(ATP sensitive potassium channel), 
leading to accumulation of potassium ions in the cytoplasm and 
depolarisation of the cell. This opens the calcium channels, influx of 
calcium into the cell and release of insulin from the secretory vesicles into 
the extracellular fluid and hence into the blood. 
The glucose sensor of the beta cell is the enzyme glucokinase. 
Inactivating mutations of this enzyme lead to failure of the beta cell to 
secrete insulin even in the face of elevated blood glucose concentrations. 
Maturity onset diabetes of young (MODY 2), a monogenic form of diabetes 
is the heterozygous state of this mutation.  Conversely, activating the 
mutations leads to hypoglycemia. 
In addition to glucose, insulin secretion can be stimulated by certain 
amino acid particularly leucine, glucagon, incretin hormones (GLP and 
GIP) and parasympathetic stimulation. Insulin itself, sympathetic 
stimulation and certain drugs are inhibitors of insulin. In normal individuals 
the most potent stimulant for suppressing insulin secretion is fall in blood 
glucose levels. 
13 
 
Insulin secretion in response to blood glucose levels occurs in two 
distinct phases. The first phase is short lived, lasting for less than 5 minutes, 
which is produced by the release of insulin from preformed secretory 
granules. This first phase is important in suppressing gluconeogenesis and 
in tackling postprandial hyperglycemia, followed by second phase, which 
lasts for 30-60 minutes, depending on the nature of glucose load. 
This second phase is produced by fresh synthesis of insulin and 
secretory granules are recruited from the storage pool. Type 2 diabetes is 
due to defect in the first phase of insulin secretion
15
. 
Insulin exerts its action on target cell by binding to insulin receptors 
on the cell membrane. The insulin receptors consist of alpha and beta 
subunits. The alpha subunits projects outside the cell surface and contains 
insulin binding sites. The beta subunit is partly intracellular and can act as a 
tyrosine kinase when insulin binds to the A subunit. This leads to auto 
phosphorylation of the receptor as well as a number of intracellular proteins, 
which include insulin receptor substrate (IRS) 1 and 2. 
The second messengers like phospholipids are activated by 
phosphorylated proteins which mediate the various actions of insulin. The 
two major intracellular pathways of insulin are the phosphotidyl 3-kinase 
(PI3K) which mediates the metabolic pathway and the adapter protein (Grb-
2-SOS) which mediate mitogenic pathway such as weight gain. 
14 
 
The most important action of insulin is the synthesis and translocation 
of glucose transporter 4(GLUT-4) to the cell membrane in adipose tissue 
and skeletal muscle, which is insulin dependent. Glucose uptake in other 
cells is insulin independent and depends upon the concentration of blood 
glucose.  
Other actions of insulin are promotion of glycogen synthesis, protein 
synthesis, lipogenesis and inhibition of glycogenolysis, gluconeogenesis, 
proteolysis and lipolysis. 
 
COUNTER -REGULATORY HORMONES 
The chief effect of these hormones is to antagonize the biochemical actions of 
insulin. The important counter-regulatory hormones are  
 Glucagon, from  alpha cells of  islets of langerhans 
 Cortisol, from adrenal cortex 
 Catecholamines (particularly epinephrine from adrenal medulla 
and sympathetic nerve endings). 
 The action of glucagon and epinephrine are quick and short lived. 
On the other hand action of cortisol and growth hormone are slow 
to act, but long lasting. Glucagon acts mainly on liver to stimulate 
glycogenolysis and cortisol acts mainly on peripheral tissues to 
promote gluconeogenesis. In type 2 diabetes, in addition to 
insulin action deficiency, glucagon excess is also noted. 
15 
 
 
PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS 
The most common form of diabetes is type 2 diabetes and constitutes 
more than 90%. The etiopathogenesis of type 2 diabetes is complex and 
unraveled. The current understanding of the pathophysiology of diabetes  
according to latest American diabetes association represents a continuum of 
clinical scenarios , ranging from severe insulin resistance (IR) with relative 
insulin deficiency to severe insulin deficiency with some degree of insulin  
resistance. It is not clear which comes first, insulin resistance or insulin 
secretory defect. 
All individuals become insulin resistance at some part of time. However, 
most of them have sufficient beta-cell reserve to overcome this IR and prevent 
the development of type 2 diabetes and individuals who develop type 2 DM 
might have a decreased beta–cell reserve, which renders them incapable of 
overcoming insulin resistance over a period of time. Insulin resistance can be 
acquired or inherited. 
Most important of IR is obesity, particularly abdominal obesity which 
again can be due to genetic or environmental factors. Certain genetic 
syndromes, use of drugs like corticosteroids are associated with diabetes. Low 
birth weight predispose to the development of diabetes. Reversible causes of 
insulin resistance include physical inactivity and chronic hyperglycemia 
(glucotoxicity).
16 
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Resistance to insulin action can occur at the level of the insulin receptor 
or in the post receptor pathways. Down regulation of the receptors as well as 
anti-insulin and insulin receptor antibodies have been implicated in the 
etiopathogenesis of type 2 DM. It is of interest that resistance seems to develop 
only to the metabolic effects and not to the mitogenic effects. 
The major contributor to beta cell dysfunction is genetic. The genes 
responsible for this impairment of beta cell function remain unknown. Even 
before the development of diabetes, beta cell dysfunction can be detected at the 
stage of impaired glucose tolerance as the beta cell defect is progressive. An 
average individual develops diabetes only after losing 50% of beta cell mass. 
Environmental factors that contribute to beta cell dysfunction include 
chronic hyperglycemia, free fatty acids, alterations in incretin axis and in utero 
malnutrition. Functional defect rather than structural defect seems to be 
responsible for the beta cell dysfunction in type 2 DM. 
In addition to insulin, two other hormone systems deserve special 
mention. The physiological antagonist of insulin is glucagon, which is secreted 
by alpha cells of pancreas in response to a variety of stimuli important one is 
decrease in blood glucose. It raises the blood glucose mainly by hepatic 
glycogenolysis and to some extent gluconeogenesis. In normal individuals, 
high blood sugar level leads to suppression of glucagon secretion. In type 2 
diabetes, this feedback inhibition does not occur leading to inappropriately high 
glucagon levels, contributing to hyperglycemia.  
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The second group of hormones “incretins”.  These are hormones 
secreted from intestinal epithelium in response to carbohydrate rich meal. They 
act on the pancreas and stimulate insulin release in response to blood glucose 
level. These are responsible for incretin effect and oral carbohydrate intake 
causes more insulin to release than intravenous glucose
17
.  
They also inhibit glucagon release from the alpha cell, slow gastric 
emptying and produce satiety and act on the central nervous system to reduce 
appetite and produce weight loss. The two important hormones in this incretin 
group are glucagon like peptide-1(GLP-1) and glucose dependent 
insulinotrophic peptide (GIP).These peptide have a shorter half life, since they 
are degraded by the enzyme dipeptidyl peptidase-4(DPP-4). 
In type 2 DM, there is a reduction in the levels of both GLP-1 and GIP; 
whereas the response to GLP-1 is intact, that of GIP is diminished or absent in 
type 2 DM.  In addition to the pathogenesis mentioned above, the role of other 
organs in the pathogenesis of type 2 DM has been termed as „ominous octet’.18 
 
METABOLIC ABNORMALITIES AND HYPERGLYCEMIA IN TYPE 2 
DM 
              Liver, skeletal muscle and adipose tissue are the major sites of insulin 
action. In short insulin promotes utilization of glucose, energy storage   as 
triglycerides in adipose tissue and as glycogen in the liver. When IR develops, 
 ACANTHOSIS NIGRICANS 
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these processes either do not occur at the appropriate rates or occur only at the 
expense of raised insulin levels. In the process of developing Type 2 DM 
compensatory hyperinsulinemia is the earliest biochemically detected 
abnormality.  
Acanthosis nigricans, a hyperpigmented velvety lesion of the skin, 
found on the posterior aspect of the neck, axillae, and groin is an important 
cutaneous marker and it is most often met with obese individuals with Type 2 
DM or prediabetes. Epidermal cell growth by insulin or insulin like growth 
factor (IGF) is postulated to the development of acanthosis nigricans and is 
often associated with skin tags. 
 
Inappropriate release of glucose due to defective insulin action in the 
liver leads to fasting hyperglycemia. Due to the action of insulin hepatic   
glucose output is completely suppressed after a meal. This suppression does not 
occur with insulin resistance, leading to postprandial hyperglycemia. 
The main acute complications are diabetic keto acidosis and non ketotic 
hyperosmolar coma. The major chronic complications of diabetes are coronary 
artery disease (CAD) 21.4%, Peripheral vascular disease (PVD) 6.3%, 
retinopathy 17.6%, nephropathy 2.2%, neuropathy 26.1%.
19 
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COMPLICATIONS OF TYPE 2 DIABETES MELLITUS 
 
 
 
Microvascular 
complications 
Macrovascular 
complications 
Other complications 
 (1) Eye Diseases 
(1) Coronary Heart 
Disease 
(1)  Gastrointestinal  
Malfunction 
(gastroparesis, 
diarrhoea) 
Retinopathy 
(nonproliferative/proliferative) 
  (2) Peripheral 
Arterial Disease 
 (2) Genitourinary 
 Dysfunction 
(uropathy/sexual 
dysfunction) 
Macular edema 
(3) Cerebrovascular 
Disease 
(3)Dermatological 
Problems 
 (2)Neuropathy   (4 Infections 
Sensory and motor (mono- 
and polyneuropathy) 
  (5) Cataracts 
Autonomic neuropathy   (6)Glaucoma 
 (3) Diabetic Nephropathy  
  (7)Periodontal 
disease 
    (8)Hearing loss 
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MICROALBUMINURIA 
The major excretory organ in the body is the kidney. Toxic molecules, 
metabolic wastes (urea and creatinine) are filtered from blood by the nephron, 
the functional unit of the kidney and extra volume of fluid is also removed to 
maintain normal blood volume. Electrolytes like sodium, potassium and 
proteins are reabsorbed. 
 Each kidney consists of one million nephrons and each nephron 
contains glomerulus and tubules. Filtering membrane of the glomerulus 
consists of three layers; the endothelium, the epithelial podocyte, and the 
basement membrane.  
The filtrate passes through the glomerular filtering membrane to reach 
the four parts of the tubular system: the proximal convoluted tubule, loop of 
Henle, distal convoluted tubule and collecting duct, where most of the 
reabsorption occurs. 
 Most of the glucose and plasma proteins gets reabsorbed in the 
proximal tubule ,concentration of urine occurs in the loop of Henle and sodium,  
potassium ions get regulated in the distal tubule
20
.  
The Blood supply to kidney is through renal arteries which branches 
into segmental arteries, then into different lobular arteries, again into 
interlobular arteries and finally divide to form afferent and efferent arterioles.  
21 
 
Afferent arterioles receive the blood, while efferent arterioles remove 
the blood, so both afferent and efferent arterioles play a key role in maintaining 
the glomerular pressure by vasoconstriction and vasodilatation. 
Transportation of the important essential molecules such as hormones, 
lipids, vitamins, hormones, minerals and exogenous substance such as drugs 
are transported by the proteins. The oncotic pressure is maintained by the 
proteins between plasma and interstitial space.  
Albumin, the carrier protein, immunoglobulin and acute phase proteins 
are the proteins present in the blood. Albumin is the most abundant, highly 
soluble, single polypeptide containing 585 amino acid sequences accounting 
for 60% of serum proteins with a concentration of 3.4 – 5.4g/dl21. 
The main contribution of colloid oncotic pressure is by albumin and its 
levels are affected by factors, insulin and cortisol. In the proximal convoluted 
tubule albumin and other proteins are reabsorbed by receptor mediated 
endocytosis. This endocytosis process is achieved by receptor complex called 
megalin-cubilin. Albumin gets attached to this complex in the apical 
membrane, an adapter at the tail of the receptor and finally internalisation of 
the ligand-receptor complex occurs. 
After internalisation an endocytic vesicle transports the formed complex 
to the endosomal compartment and the protein complex is dissociated by 
acidification. In the lysosome, albumin gets degraded and the original 
aminoacids are returned to the blood stream. 
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Almost all the filtered albumin is reabsorbed by the kidney and only a 
small amount is excreted. Normoalbuminuria is defined when albumin 
excretion occurs at a rate of <30 mg/day; <20 microgram/minute in an 
overnight urine collection; <20mg/l on spot urine specimen or ACR 
<2.5mg/mmol in males or <3.5mg/mmol in females. 
However in certain pathological conditions like diabetes, chronic renal 
disease, and hypertension, changes produced in glomerulus and tubules lead to 
the excretion of larger amounts of albumin leading to albuminuria. Albumin 
excretion can be expressed as a concentration of albumin in urine as mg/day or 
as albumin to creatinine ratio.   
          Microalbuminuria is defined when  albumin excretion occurs at a rate 
of 30-300 mg/day; 20-200microgram/minute in a overnight urine collection 
;20-200mg/L on spot  urine specimen or ACR 2.5 to 25mg/mmol in males  or 
3.5 to 25 mg/mmol in females 
22
. 
          Macroalbuminuria or gross proteinuria is defined as levels exceeding 
300mg/day or 200mg/l in spot urine or albumin-creatinine ratio (ACR) > 25 
mg/mmol. This reflects a state of renal function deterioration. Protein excretion 
can be measured as total protein or specifically as albumin. 
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PATHOGENESIS 
The exact pathology underlying the microalbuminuria in diabetes is not 
clearly understood. The main pathology of microalbuminuria in diabetes 
mellitus is endothelial dysfunction and insulin resistance. Hyperglycemia is the 
initiating factor in the pathogenesis of microalbuminuria. So microalbuminuria 
is reversible by improved glycemic control. 
 
          23
Adverse effects of hyperglycemia is mainly diverse metabolic pathways 
due to 
a) Advanced glycation end products, 
b) Increased polyol pathway activation, 
c)  Protein kinase C activation , 
d) Increased flux through hexosamine pathway. 
In addition to hyperglycemia, several other factors like increased blood 
pressure, morbid obesity, heavy exercise, various illnesses both acute and 
chronic and heart failure causes microalbuminuria.  
Microalbuminuria occurs only after endothelial dysfunction. Degree of 
proteinuria poorly correlates with the podocyte injury.  Indeed proteinuria can 
occur in the complete absence of structural changes of podocytes in type 2 
diabetes. 
 Albumin excretion increases annually at a rate of about 20% in type 2 
diabetes mellitus. Albumin excretion is determined by the amount filtered 
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across the glomerular capillary membrane and the amount reabsorbed by the 
tubular cells. 
 
     The passage of macromolecules across the glomerular capillaries is 
governed by the size and charge selective properties of glomerular capillary 
membrane and the hemodynamic forces operating across the capillary wall. 
Podocyte specific proteins in the regulation of the selective permeability have 
been recognised. 
Until now, pathology of microalbuminuria in diabetes is related to 
insulin resistance or insulin resistance and obesity. Recently proinflammatory 
cytokines produced by visceral adipocytes (adipokines) is emerging as an 
important mediator of increased cardiovascular risk factor
24
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DETECTION 
Microalbuminuria can now be detected by conventional dipstick 
method. These strips are inexpensive, easy to use but not accurate. Various 
other techniques are also available like immunoassays, and chromatographic 
techniques like high performance liquid chromatography. 24 hour urine 
collection is ideal and the results are accurate (Witte et al.), but complete 
compliance is not possible. 
Overnight albumin excretion rate is simpler, easier way of timed 
microalbuminuria measurement (Dyer et al.,). The advantage of overnight urine 
collection is stable albumin excretion because of limited bed time movement. 
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 Urinary albumin concentration (UAC) or Albumin creatinine ratio 
(ACR) on random samples (American diabetes association,) or first voided 
morning sample are more commonly used methods (Lambers Heerspink et 
al). The easiest and convenient method for patients and practitioners is random 
spot collection. In this method the patients are instructed to collect the first 
voided urine after retiring from the bed and this method removes the biological 
variations, reflects the real magnitude of albumin excretion
25
. 
 
                   Timed urine collection Spot morning urine specimen 
Albuminuria 
level 
24-hour 
albumin 
excretion 
(mg/day) 
Overnight 
albumin 
excretion 
(µg/min) 
UAC 
(mg/L) 
ACR 
 
 Gender mg/m
mol 
mg/ g 
Normal <30 <20 <20 Male 
female 
<2.5 
<3.5 
<20 
<30 
microalbuminuria 30-300 20-200 20-200 Male 
female 
2.5-25 
3.5-25 
20-200 
30-200 
Gross proteinuria >300 >200 >200 Male 
female 
>25 
>25 
>200 
>200 
 
 
In Studies like PREVEND (Prevention of Renal and Vascular End stage 
Disease), researches compared ACR and UAC, both from first morning sample 
and random sample and the outcome was compared with 24-hour urine 
collection (Witte et al.,). First morning ACR sample correlated   with 24-hour 
urinary albumin excretion (UAE).They are used in predicting morbidity and 
mortality associated with cardiovascular disease. 
26 
 
Several international guidelines recommend repeated samples for 
diagnosis of microalbuminuria (two of three samples must be positive) to 
remove the confounding factors (National Collaboration Centre for Chronic 
Conditions, 2008). But this seems difficult practically and single sample is used 
for majority of studies.  
 
PREVALENCE OF MICROALBUMINURIA IN TYPE 2 DIABETES 
MELLITUS 
American Diabetes Association, 2011 has recommended 
microalbuminuria screening for the management of diabetes in majority of the 
clinical guidelines. United Kingdom Prospective Diabetes Study (UKPDS) 
studied 5097 type2 diabetes patients from different ethnic groups for the 
prevalence of microalbuminuria and found it was 17% after 5 years, 25% after 
10 years, and 28% after 15 years.  In a population based study of type 2 
diabetes Vipputuri et al
26
, showed the prevalence of microalbuminuria and 
proteinuria were, 31%, and 12% respectively. 
Prevalence of microalbuminuria varies according to the ethnicity and it 
is commonly found in Asians and black populations compared with whites 
(Summerson et al). A comparative study between white Europeans and south 
Asian population revealed that microalbuminuria was more prevalent in south 
Asians (31%vs 20%) (Dixon et al). No difference between age, sex, and blood 
pressure was noted among individuals in this study.  
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Tillin et al
27
 compared the prevalence of UAE among the Africans, 
south Asians, and white Europeans and showed that microalbuminuria was 
more prevalent among African people than south Asians and Europeans. In 
various studies done on diabetic patients attending diabetic clinic, showed the 
prevalence of microalbuminuria was higher among Asian population than 
white Europeans.   
The relation between microalbuminuria and gender varies. Pontremoli 
et al., 1997 have shown greater prevalence in males. Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Intervention and Complications 
(DCCT/EDIC) have also shown that urinary albumin excretion in male gender 
is greater and it is associated with central obesity. EPIC-Norfolk study, the 
prevalence was higher among females (Yuyun et al). Calvino et al,. reported 
that there was no difference among either sex. 
 
MICROALBUMINURIA AND RENAL FUNCTION 
Deterioration of renal function is best recognised by microalbuminuria. 
Levey et al, reported that microalbuminuria is associated at an early stage of 
the kidney disease. Astor et al, recommended the use of albuminuria with 
eGFR for the prediction of End Stage Renal Disease (ESRD). Behrane et al,
 28
 
2011 reported recently reported the same. Therefore, high risk individuals 
should be routinely screened to identify microalbuminuria earlier to prevent or 
delay possible progression to ESRD. 
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MICROALBUMINURIA AND CARDIOVASCULAR RISK 
Since microalbuminuria reflects the generalised endothelial dysfunction, 
it is now linked with cardiovascular abnormalities like CHD, myocardial 
infarction, heart failure, hyperlipidemia,   and atherosclerosis. Klausen et al., 
2004 suggested the prognostic value of microalbuminuria for ischemic heart 
disease involving different population. After adjusting for known factors such 
as blood pressure, lipids, gender and BMI, the relative risk developing ischemic 
heart disease associated with microalbuminuria was 3.5. 
The study by Apostolovic et al
29
, documented that about one third 
patients with myocardial infarction had increased UAC and it was a strong 
predictor for myocardial infarction complications including mortality. 
 
INFLAMMATION 
The word inflammation meaning ̏ setting on fire ̋  (16 century) is a 
local protective response to tissue injury. These processes have been known 
since Egyptian times 2500B.C. The cardinal signs of inflammation are rubor, 
calor, tumour, dolor was described by Celsus in first century A.D, and loss of 
function was later added by Galen 130-200 A.D. Vasodilatation, increased 
capillary permeability and interstitial fluid permeability, accumulation of 
leucocytes and stimulation of nerve endings by mediator such as substance P 
are the microscopic findings. 
Ross et al
30
 showed that cells such as monocytes, macrophages, T-cells, 
endothelial cells, release inflammatory mediators including cytokines and 
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chemokines during the process of plaque formation. This develops an 
inflammatory response in the vessel. 
  Adipose tissue secretes cytokines which is responsible for insulin 
resistance in liver, skeletal muscle, and vascular endothelial tissue and 
ultimately results in clinical expression of type 2 DM and cardiovascular risk 
Endothelial production of adhesion molecules including E-selectin, 
intercellular adhesion molecules (ICAM-1), Vascular adhesion molecule 
(VCAM-1) are the crucial mediators of endothelial dysfunction in capillary and 
arterial endothelium are stimulants by TNF-alpha, IL-6 and CRP apart from 
promoting insulin resistance (Gabay and Kushner ;Targher et al )
31
. 
Tissues produce major proinflammatory cytokines like IL-6, activated 
leucocytes, adipocytes and endothelial cells. IL-6 induces gluconeogenesis, 
hyperglycemia, and compensatory hyperinsulinemia in rodents. Subcutaneous 
administration of   recombinant IL-6 (Tsigos et al) produces similar results in 
humans. 
Inflammation plays a major role in the etiology of type2DM and 
demonstrated an elevated level of IL-6 and CRP in type2 DM (Sattar et al). 
Metabolic syndrome and type 2 DM are associated with markers of 
inflammation and levels of inflammatory markers were due to insulin 
resistance, but not due to insulin secretion. 
A number of studies have associated routine hematological parameters 
with type 2 DM and cardiovascular disease and found that a strong association 
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exists between insulin resistance, cardiovascular disease and hematological 
parameters. 
 
INFLAMMATORY MARKERS 
Libby et al
32
, mentioned that great work has been done to detect the 
inflammatory markers that are risk factors for coronary heart disease. 
Fibrinogen, C - reactive protein, total leucocyte count and Interleukin-6 are the 
most widely used markers and these are the acute phase reactants. Their 
presence in the blood reflects the current inflammatory state of the individual, 
with leukocyte count and C-reactive protein routinely used to measure the 
inflammation. 
 
INFLAMMATION AND TYPE 2 DM 
Diabetic individuals are at increased risk for cardiovascular disease 
because of atherosclerosis due to Advanced Glycation End products (AGE). 
AGE‟s   are accumulated due to hyperglycemia and indicates metabolic burden, 
oxidative stress, and inflammation (Xiong et al, Stern et al)
 
.
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AGE‟s and AGE specific receptors produces inflammatory reactions and 
endothelial dysfunction. AGE‟s produces unusual cross links in collagen 
leading to vascular stiffness. 
Recent studies have shown the increased serum levels of AGE‟s in 
type2 DM patients with Coronary Heart Disease (CHD). AGE‟s accumulate in 
31 
 
coronary atherosclerotic plaques and cardiac tissue of type 2 DM in several 
immune histochemistry studies (Nakamura et al, Grillo and Colombatto ). 
Glucose reacts chemically and nonenzymatically with proteins in vivo to 
form amadori products. Amadori products are rearranged to form AGE‟s 
(Letonja et al , Petrovic et al )
34
. 
The significance of oxidising conditions and reactive oxygen species 
involved in the formation of  glycol oxidation  products which are a major class 
of AGE‟s that accumulate in diabetic tissues was studied by Baynes and 
Thorpe el al,. 
           
             Diabetic microvascular complications are capillary basement 
thickening and hypertrophy of extracellular matrix. Hyperglycemia leads to 
accumulation of AGE‟s in tissues causing tissue damage and diabetic 
complications (Meerwaldt et al ).
35
 
Excessive production of free radicals like reactive oxygen species, 
increased oxidation of substrates and auto oxidation of glucose leads to 
oxidation stress in diabetes. This free radical leads to reduction of nitric oxide, 
leading to vasoconstriction and endothelial dysfunction 
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 INFLAMMATION AND LIPOPROTEINS 
Earlier the complement complex C5b-9 gets activated in the 
atherosclerotic rich lipid core. Local cellular gene expression and behavior are 
influenced by cytokines. The production of collagen by smooth muscle is 
enhanced by Platelet Derived Growth Factor (PDGF), fibroblast growth factor, 
transforming Growth Factor –beta (TGF-β) and macrophage inflammatory 
responses were suppressed.
 
        CD40 ligand on the T lymphocyte exerts a critical pro-inflammatory effect 
on atherosclerosis and gamma interferon (IFN γ) modulates the process of 
atherosclerosis. Endothelial anticoagulant- procoagulant balance is shifted 
towards procoagulant effect by inflammatory cytokines interleukin -1(IL-1β), 
and tumour necrosis factor –α (TNF-α). 
NFKB family integrates various factors into inflammatory responses. 
Genes with NFKB response elements are vascular cell adhesion molecule-1, 
macrophage chemo tactic peptide -1, tissue factor are involved in  proliferation 
of  cell. 
Atherosclerosis is a chronic form of inflammation present in the wall of 
the artery and epidemiological studies linked circulating inflammatory markers 
and cardiovascular events that were used in the prediction of cardiovascular 
risk taking into account other risk factors (Hansson et al).
36
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                      CARDIOVASCULAR RISK FACTORS 
                    The main modifiable risk factors are
37
 
 Elevated blood cholesterol 
 High triglycerides 
 Elevated blood pressure 
 Diabetes 
 Smoking 
 Obesity 
 Sedentary life style 
 
 
LIPOPROTEIN 
Lipoprotein plays a key role in atherosclerosis and 60-75% of diabetic 
people die of myocardial infarction or stroke, therefore lipoprotein reduction 
can   reduce the diabetic cardiovascular risk
38
.    The stiffness and viscosity of 
lipid bilayer of membrane is increased when cholesterol / phospholipid ratio 
gets increased resulting in decreased permeability of cell membrane to water 
and other organic molecules. 
     Apart from lipoprotein abnormalities atherosclerosis, a serious complication 
of diabetes is due to the accumulation of advanced glycation end products in 
arterial tissue and numerous gene products try to restore the membrane 
homeostasis. So in atherosclerotic plaques these mechanism fail and vascular 
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cells may die because of over accumulation of cholesterol which disrupts 
critical membrane function.  
  The fuel for skeletal muscle, heart muscle, and most other tissues is 
supplied by fatty acids. Esterification of these fatty acids forms triglycerides 
and cholesterol esters for transportation and storage which is water insoluable.  
Over accumulation of cholesterol or fatty acids resulting in disruption of 
cell membrane structure or function is prevented by esterification reactions, 
representing cellular defense mechanism. Triglycerides and cholesterol esters 
are non toxic because of their minimal presence in cell membrane as oily 
droplets. 
                      
 
 APOLIPOPROTEINS AND LIPOPROTEINS  
         The plasma lipoproteins are the pseudomicellar structure consisting of 
cholesterol, cholesterol esters, triglycerides, and phospholipids packed with 
specific proteins (apoproteins) for circulatory transport.  
Based on the equilibrium densities by ultracentrifugation plasma 
lipoproteins are divided into chylomicrons, VLDL, HDL, and LDL. 
Chylomicrons, VLDL have abundant core lipid than surface phospholipid and 
HDL have more surface phospholipid compared to core lipid. 
The lipoprotein structure and lipid transport are determined by the 
apoproteins. Apolipoprotein A-I and Apo-B are considered as basic structural 
apolipoproteins. The production and release of VLDL is stimulated, attributing 
  
 
 
 
 
SMALL LDL 
 
 
 
    lbLDL – Large buoyant LDL   sdLDL  - Small Density LDL 
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to hypertriglyceridemia leading to have low levels of high density lipoprotein 
(HDL) in their circulation. Also, higher levels of VLDL lead to increased 
exchange of cholesterol ester and triglyceride between VLDL and low density 
lipoprotein (LDL), increasing the triglyceride content of LDL and making them 
more susceptible to degradation by hepatic lipase, leading to formation of small 
dense LDL particles.  
The lipid profile in type2 DM individual is characterised by high 
triglyceride levels, low HDL cholesterol levels, and normal levels of LDL 
cholesterol, with relative increase in the number of highly atherogenic small 
dense LDL particles.  
In adipose tissue defective insulin action leads to excessive breakdown 
of triglycerides and formation of non–esterified fatty acids (NEFA). High 
levels of NEFA can stimulate gluconeogenesis in liver and can reduce insulin 
stimulated glucose uptake by tissues. Even though lipolysis occurs, ketone 
bodies are not produced in type 2 DM as insulin deficiency is not absolute and 
even a small amount of insulin is sufficient to prevent the formation of ketone 
bodies  than to maintain glucose homeostasis. 
Insulin has beneficial effect on platelet function, vascular integrity and 
the autonomic nervous system. Insulin resistance can adversely affect all these, 
causing increased susceptibility to ASCVD seen in type2 DM. 
Lipoprotein (a) resembles low density lipoprotein and Lipoprotein (a) 
account for most of plasma “LDL” is associated with coronary and other 
atherosclerotic disease. In diabetes and insulin resistance Lipoprotein (a) 
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alterations occurs, but they play a minor role. Lipoprotein (a) measurement 
plays a key role to evaluate a cardiovascular risk
 
due to genetic, and 
unmodifiable influence.
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LIPOPROTEINS AND ATHEROSCLEROSIS 
The concentration of LDL in the arterial intima is abundant, stagnant 
and its concentration is equal to its concentration in blood plasma. In other 
tissues it is present to about one tenth of plasma. Collagen, elastin, 
proteoglycans of arterial intima are exposed to greater concentration of LDL.  
Arterial intima is lacking the lymphatic vessels and so excess 
macromolecule species are not washed away. Enzymatic, Oxidative and other 
process disrupting the individual LDL particles are increased by greater 
residence time and high levels of LDL. Therefore the arterial intima was 
considered as a pool for LDL
40
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ACCUMULATION OF LIPID-LESION PROGRESSION 
Earliest atherosclerotic lesions that appear in the coronaries and aorta of 
teenagers are the fatty streaks. These lesions serve as precursors for advanced 
lesions but never thicken the intima nor predispose to thrombosis. 
Histologically, macrophages filled with lipids and smooth muscle bearing 
lipids are present in the fatty streaks. Immune process, smoking, or 
hypertension cellular adhesion molecules are upregulated by 
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hypercholesterolemia, and macrophages from circulating monocytes move 
from blood into the fatty streaks.  
Starting at the age of 20, fibrous plaque begins to appear from pre-
existing fatty streaks. The intimal thickening is due to the proliferation of 
smooth muscle cells, macrophages, collagen, and fibrous tissue proteins 
Once the plaque begins to grow and impinge on the arterial lumen, 
entire artery undergoes arterial enlargement which is depends on endothelial 
regulation of arterial lumen produced by velocity of blood and shear rate of 
wall.
41
 Collagenous lesion extends around the circumference of the artery due 
to the failure of compensatory mechanisms and diabetes, leads to the failure of 
endothelial dependent relaxation of arteries resulting in increased atherogenic 
events.
 
Lipid rich core is the most dangerous part of atherosclerotic lesion. The 
fibrous cap is eroded by lipid accumulation and cellular apoptosis 
42
. The blood 
is directed into the core when this cap ruptures. 
 
PLAQUE STABILIZATION 
Atherosclerotic intimal thickening is decreased by atherosclerotic 
regression resulting in reduced stenosis and this causes plaque stabilization.  
Hypercholesterolemia interferes with normal endothelial function and 
decrease in LDL cholesterol normalizes relaxation produced by endothelial 
tissue improving the resistance produced by thrombosis also. 
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Lowering of lipid causes disappearance of macrophage foam cells from 
the lesions thereby decreasing the propensity to rupture leading to plaque 
stabilization and preventing other   atherothrombotic events. 
 
CHOLESTEROL 
The absorption of 30-60% of cholesterol entering the intestine is 
unregulated. The daily biliary cholesterol is 900 mg and dietary cholesterol is 
only about 300-400 mg. Bile acids solubilise cholesterol in the intestinal lumen 
to form mixed micelle.  Incorporation of the micelles is competitively inhibited 
by plant sterols and stanols which reduce plasma cholesterol. 
Intestinal cholesterol asses into the absorptive cells by facilitated 
diffusion involving the recently discovered protein like Niemann pick. 
Cholesterol present in the cells undergoes esterification which is secreted into 
intestinal lymph.  Out of this one third of cholesterol is added to total body 
stores from the diet and two thirds is synthesised.  
 
REVERSE CHOLESTEROL TRANSPORT AND HDL 
Most of the cholesterol in the body is made in the peripheral tissue cells. 
Excess cholesterol which cannot be degraded or metabolized by most cells is 
transported for disposal to liver. This is “reverse cholesterol transport” and 
mechanism of this is not clearly understood. Heredity, hormones, obesity and 
exercise all affect HDL2 primarily
43
.  
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LDL AND HEPATIC CHOLESTEROL METABOLISM  
Reverse cholesterol occurs in the liver and from here VLDL and LDL is 
delivered to body tissues. In the tissues VLDL is transformed into IDL and 
subsequently into LDL. LDL particles are taken up by receptor mediated 
endocytosis by peripheral tissues.  
 In liver about two thirds of total LDL catabolism occurs as it contains 
LDL receptors. LDL concentration in the plasma is often decreased by 
upregulating LDL catabolism and hepatic LDL receptor activity, than 
decreasing LDL production. 
Hepatic cholesterol balance requires input and output. Bile acids 
undergo an enterohepatic circulation. The major route of cholesterol 
elimination is by faecal loss, bile acids, and their colonic bacterial degradation 
product.  
Increased cholesterol excretion leads to the conversion of more amount 
of cholesterol to bile acids and more cholesterol is also synthesised in the liver. 
Ultimately cholesterol present in liver decreases, LDL receptors are increased 
and LDL level in plasma falls.  
 
TRIGLYCERIDES 
For intestinal absorption of fat, pancreatic lipase has to hydrolyse 
triglycerides to fatty acids and monoglycerides. In the intestinal lumen bile 
salts help in lipolysis and absorption of fatty acids by forming micelles. Inside 
the cells of intestine present in the mucosa, fatty acids are reesterified to 
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glycerol and arranged in chylomicrons in the triglyceride core. These 
chylomicrons enter the circulation via thoracic duct. 
Chylomicrons carry triglycerides synthesised in the gut and VLDL carry 
triglycerides by the liver. Lipoprotein lipase metabolizes both these triglyceride 
rich lipoproteins in the peripheral circulation. Lipoprotein lipase enzyme 
hydrolyses only the triglycerides but not the cholesterol esters or fatty acids and 
so these are released into the circulation to enter into the endothelium of 
capillaries and parenchyma of tissue. 
So triglyceride rich lipoprotein shrinks in size and hepatic cells take up 
the chylomicron remnants. In the hepatocytes VLDL is converted to LDL by 
the action of hepatic lipase. 
 Hypertriglyceridemia occurs when lipoprotein lipase is absent 
genetically. Severe deficiency in insulin can also decrease activity of 
lipoprotein lipase with the same result. 
Insulin and plasma free fatty acids strongly influence the metabolism of 
hepatic free fatty acid and triglycerides. The liver takes the plasma free fatty 
acids and incorporates into triglycerides and forms VLDL. 
 Obesity is associated with high plasma triglyceride level because of 
high plasma free fatty acids. Deficiency in insulin, intake of alcohol excess also 
increases secretion of VLDL and plasma triglyceride levels are increased by 
increased plasma free fatty acid levels. 
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DIABETIC DYSLIPIDEMIA 
The diabetic dyslipidemia is increased concentration of lipoproteins rich 
in triglycerides, decreased concentrations of HDL, LDL and HDL becomes a 
smaller, denser particles.  
Increased movement of fatty acids to liver from adipose tissue is the 
primary abnormality in diabetic dyslipidemia. Hormone sensitive lipase in 
adipocytes is suppressed by insulin resistance, insulin deficiency or both, which 
causes release of NEFA into plasma.  
Normally liver packs and exports the fatty acids as triglycerides in Very 
Low Density Lipoprotein, and VLDL levels are raised in plasma. By action of 
lipoprotein lipase the fatty acids from VLDL triglycerides are transported back 
to adipose tissue. However in insulin resistance or insulin deficiency state 
lipoprotein lipase activity is reduced and VLDL triglyceride level in plasma is 
raised. 
Small LDL is formed as the result of major pathophysiological process. 
Per particle of Very Low Density Level in diabetic individuals or insulin 
resistant individuals have more triglycerides than VLDL in an average 
individual. Secondly, the exchange of neutral lipids in core- triglycerides and 
cholesterol ester in particles of lipoprotein is mediated by cholesterol ester 
transfer protein (CTEP). 
When VLDL is abundant, then triglycerides replace cholesterol ester in 
both HDL and LDL. The hepatic lipase removes the lipid present in the core of 
triglyceride rich LDL and HDL. Hence, both LDL and HDL get reduced in 
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size. Epidemiological data suggest large buoyant LDL is less atherogenic than 
small dense LDL. Increased permeation of arterial endothelium, prolonged 
residence time of the particle in plasma with lower levels of antioxidants leads 
to the accumulation of lipids.
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     Lipoprotein lipase effectively clears the dietary fat from the blood. But, 
lipoprotein lipase activity is greatly diminished in insulin deficiency or in 
insulin resistance and chylomicrons may be found 24 hours after last ingestion. 
Enormous accumulation of chylomicrons occurs in blood when this happens 
for a prolonged period. 
Pancreatic lipase is activated locally and fatty acids are generated 
forming soaps (fatty acids generator) by detergent action of pancreatic lipase 
and more digestive enzymes are released, that lead to a more vicious damage. 
Hypertriglyceridemia is blood triglycerides level >150 mg/dl. The risk of 
pancreatitis increases above triglyceride level of 2000mg/dl. The production 
and release of VLDL is stimulated, attributing to hypertriglyceridemia resulting 
in low levels of high density lipoprotein (HDL) in the circulation. 
Also, higher levels of VLDL lead to increased exchange of cholesterol 
ester and triglyceride between VLDL and low density lipoprotein (LDL), 
increasing the triglyceride content of LDL and making them more susceptible 
to degradation by hepatic lipase, leading to formation of small dense LDL 
particles. The lipid profile in type2 DM individual is characterised by high 
triglyceride levels, low HDL cholesterol levels, and normal levels of LDL 
cholesterol, with relative increase in the number of highly atherogenic small 
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dense LDL particles. This „diabetic dyslipidemia’ is one of the major factors 
underlying the increased incidence of atherosclerotic cardiovascular disease 
(ASCVD) in type2 DM.
45 
 In adipose tissue defective insulin action leads to excessive breakdown 
of triglycerides and formation of Non–Esterified Fatty Acids (NEFA). High 
levels of NEFA can stimulate gluconeogenesis in liver and can reduce insulin 
stimulated glucose uptake by tissues.  
According to guidelines of ADA and American Heart Association, the 
target lipid values in diabetic individuals (age >40 years) without 
cardiovascular disease should be as follows: LDL 100 mg/dl (< 2.6 mmol/L); 
HDL 40 mg/dl (>1 mmol/L in men) and 50 mg/dl (>1.3 mmol/L) in women; 
and triglycerides150 mg/dl (<1.7 mmol/L). In patients >40 years, the ADA 
recommends addition of a statin, regardless of the LDL level in patients with 
CHD and those without CHD, but who have CHD risk factors
46
. 
If the patient is known to have CHD, the ADA recommends an LDL 
goal of70 mg/dl (<1.8 mmol/L) as an "option". Older studies with fibrates 
increased the efficacy, but recent trials have not shown a benefit of this class of 
agents. 
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HYPERTENSION 
Hypertension is the most common co-morbid condition present along 
with diabetes. It is a major risk factor for both microvascular and 
macrovascular complications of diabetes. The prevalence of hypertension is 
1.5-2 times greater in patients with diabetes compared to non diabetic patients. 
The prevalence of hypertension in India is estimated to be as high as 30%.most 
worrying is that “Rule of halves” is applicable to diabetes which states that 
50% of hypertension is unaware that they have hypertension, 50% of known 
hypertensive‟s take treatment and only 50% who take treatment are under 
control
47
. 
National Health and Nutrition and Examination Survey (NHANES) 
1999 – 2000, states that 43% women and 31% of men with diabetes had high 
blood pressure. Incidence of hypertension is increased approximately by 50% 
in diabetes and it is both due to insulin resistance and   hyperinsulinemia. 
Hypertension forms an important risk factor for cardiovascular disease 
including coronary artery disease, cardiac failure, cerebrovascular accidents 
and peripheral vascular disease. According to Framingham heart study when 
the SBP is increased by 20 mmHg there is a chance of 56% increased risk for 
cardiacfailure as proposed by Adler et al
48
 
          Hypertension in patients with diabetes, compared to those without 
diabetes, has unique features such as increased salt sensitivity, volume 
expansion, loss of nocturnal dipping of blood pressure and pulse, increased 
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propensity to proteinuria, orthostatic hypotension, and isolated systolic 
hypertension. 
 
Pathophysiology of hypertension in diabetes 
Hypertension and diabetes may be founded   in the co-segregation of 
genes predisposing to both hypertension and diabetes. Fat and carbohydrate, 
influences the activity of the sympathetic nervous system. Premature rise in 
systolic blood pressure in people with diabetes associated with premature 
widening of pulse pressure. This has been attributed to various mechanisms 
including an age related decline in endothelial dysfunction and progressive 
accumulation of AGE‟s. 
Ageing, mechanical strain, activation of the sympathetic nervous system 
and the rennin angiotensin-aldosterone system, along with glucose 
concentrations may play a role in promoting vascular matrix accumulation.  
Increased arterial stiffness has profound effects on blood pressure and 
increases the vascular load on heart and the coupling efficiency between the 
heart and vasculature. This premature stiffing of the aorta in diabetes explains 
the earlier development of systolic hypertension and a wide pulse pressure in  
diabetic subjects when compared with non diabetic population. It also renders 
the systolic pressure more difficult to control with drug therapy. 
 
 
 
  
 
PATHO PHYSIOLOGY OF HYPERTENSION 
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Staging of hypertension
49 
Joint national committee report VII (JNCVII): classification of hypertension 
(adults >18 years of age). 
 Systolic BP(mmHg) Diastolic BP(mmHg) 
Normal <120 <80 
Prehypertension 120-139 80-89 
Stage1 hypertension 140-159 90-99 
Stage2 hypertension ≥160 ≥100 
 
-Systolic BP >140 mmHg is a more important risk factor for CVD than 
diastolic BP. 
   -The risk of CVD doubles with every increase of 20/10mmHg beginning at 
115/75mmHg. 
SMOKING 
The combination of type 2 diabetes and smoking speeds up the rate of 
complications especially microvascular and macrovascular disease. Smoking 
with diabetes increases the risk of stroke, heart attack, peripheral vascular 
disease, kidney failure and diabetic eye disease. 
Smoking leads to narrowing of blood vessels and damages the blood 
vessel walls. Nicotine causes constriction of blood vessels and release of 
hormones such as catecholamine which increases the blood pressure. Blood 
pressure in diabetes is hard to control because of accelerated blood vessel 
47 
 
damage. Smoking places additional strain on the body‟s ability to control blood 
pressure and smoking increases the insulin resistance. 
Effects of smoking related to diabetes
50 
 Increased heart rate 
 Increased LDL (bad) cholesterol. 
 Reduced HDL cholesterol 
 Raised blood pressure 
 Increased platelets –blood is more viscous and likely to clot 
 Atherosclerosis- narrowing of the arteries 
 Increased insulin resistance. 
 
                                        OBESITY 
Obesity has been described as the major pandemic of the 21st century. 
30% of the population in most developed countries is obese. Studies from 
various parts of India indicate that 20-50% of the urban population is either 
obese or overweight. As more and more individuals and family break out of the 
grip of poverty, the prevalence rates of obesity can also be expected to go up.  
Obesity is defined as an excessive accumulation of fat in adipose tissues, 
leading to medical illness, which occurs when there is an imbalance between 
“energy intake” and “energy expenditure”.  
 
 
 
  
OBESITY 
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 Energy expenditure are determined by  
                              (i)  Thermogenic effect of food   
                               (ii)  Physical activity  
                               (iii)  Basal metabolic rate  
 The susceptibility of an individual to become obese in response to 
environmental factors is influenced by specific genes. Adipose tissue, muscle, 
liver, regulatory centre of the brain all play an important role in obesity.  
 
BMI represents relationship between weight and height. More  than 
BMI specific distribution of fat whether central or abdominal obesity is more 
important. 
 
BMI ASSOCIATED DISEASE RISK AND WHO CLASSIFICATION OF 
OBESITY 
                         Obesity class BMI(kg/m2) Risk 
Underweight  <18.5 Increased 
Normal  18.5-24.9 Normal 
Overweight  25-29.9 Increased 
Obesity I 
II 
30-34.9 
35-39.9 
High 
Very high 
Morbid obesity III >40 Extremely high 
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Additional risk: (i) waist circumference > 90 cms in men and > 80 cms  
  in women 
        (ii) Poor aerobic fitness 
        (iii) More than 5 kg weight gain between 18-20 years of age 
     (iv) Descent of Southeast Asia 
 
INDIAN CLASSIFICATION OF OBESITY
51
 
 
 
 
 
 
Obesity affects each and every organ and in particular, it is a major 
cardiovascular risk factor. The risk factor for obesity includes hypertension, 
diabetes, lipid abnormality, fibrinogen excess and markers of inflammation. 
The hall mark of cardio-metabolic syndrome is insulin resistance. 
 
Types of obesity
52 
Android or central or visceral obesity-body resembles the shape of an 
apple. The fat gets accumulated mainly above the waist. 
Gynoid obesity- the body resembles the shape of a pear i.e. the fat gets 
accumulated below the waist. 
BMI(Kg/m²) Classification 
18.5-22.9 Normal 
   23.0-24.9 Overweight 
    25.0-29.9 Obese 
  
 
 
 
Android Gynoid 
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Android or central obesity is strongly associated with the metabolic 
syndrome with the metabolic syndrome and increased risk of CVD. BMI 
cannot differentiate the two types of obesity
 
Use of WC or WHR is therefore recommended for diagnosis of central 
obesity. From convenient point of view, WC is preferred. For Indians, the cut-
off of WC was kept at 90 cm (males), 80 cm (females). 
           In spite of having lower body weight and BMI than their western 
counterparts, Asian Indians have found to have more type2 diabetes. This 
paradox has led to the concept of the “Asian Indian phenotype”. As for the 
given body weight, Asian Indians have higher waist circumference, higher 
visceral obesity, more insulin resistance and more diabetes than their Caucasian 
counterparts. That is, the “thin fat Indian” may be physically lean but he is 
metabolically obese. 
 
Diabetes and obesity 
Obesity particularly visceral obesity is a strong risk for type 2 diabetes. 
Increased depots of visceral adipose tissue lead to increased delivery of free 
fatty acids to the liver, which lead to the development of insulin resistance in 
this organ.  
Unlike subcutaneous fat, visceral fat is metabolically active which 
releases a variety of adipocytokines and inflammatory mediators which cause 
further reduction in insulin sensitivity. High levels of FFA can also inhibit 
insulin secretion from the pancreas leading to “lipotoxicity”. 
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STUDIES RELATED TO MICROALBUMINURIA 
           According to John et al
53
 study male sex, old age, longer duration of 
diabetes, poor glycemic control, and raised blood pressure were risk factors for 
microalbuminuria. 
Vijay et al
54
., showed  that duration of diabetes, systolic and diastolic 
blood pressure, age of the patient, serum creatinine with proteinuria are the risk 
factors. The association of glycemic control with microalbuminuria has been 
established by various studies. 
 Jafer et al
55
, .2009 have shown that strong association exists between 
microalbuminuria and major ECG changes  and importance of screening Indo-
Asian subjects for microalbuminuria   in subjects with hypertension, diabetes, 
obesity and tobacco users for unmasking underlying CVD.     
           Gupta et al
56
reported that microalbuminuria is associated with raised 
HbA1C.  HbA1C is increased when duration is increased or in uncontrolled 
diabetes. So these individuals have microalbuminuria   positive.  
UK based population study showed that microalbuminuria and gross 
proteinuria predicted future episodes of CHD with hazards ratios of 1.36 and 
1.59 respectively (Yuyun et al,)
 57
. 
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STUDIES RELATED TO INFLAMMATION 
Epidemiological studies begins to examine the hypothesis “elevated 
baseline inflammation predicts risk of coronary vascular disease. Various 
studies have shown the risk predictors of coronary heart disease are total 
leukocyte count (Wheeler et al, 2004), C-reactive protein,leucocyte count 
(Danesh et al)
58
and fibrinogen (FSC 2005). 
Full blood count including red cell count, white cell count, C-reactive 
protein, lipid profile, including HDL, LDL, triglycerides, HbA1C,are all 
positively correlated with increasing cardiovascular disease in type2 DM 
(Kumar and Clark )
59
. 
Elevated basal levels of some mediators like cytokines such as 
interleukin -6 (IL-6) or tumour necrosis factor , soluble  adhesion molecules 
and  downstream acute phase reactants such as CRP, fibrinogen and serum 
amyloid A (SAA) are associated with elevated risk of cardiovascular 
events(Libby et al,)
60
..                     
Tumour necrosis factor and interleukin 6 (IL-6) are produced by 
adipocyte produces an acute phase response, that leads to an increased 
production of CRP, a sensitive marker of low grade systemic inflammation 
(Hernández et al )
61
. 
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 STUDIES RELATED TO CARDIOVASCULAR RISK AND DIABETES 
              Henock Ambachew et al 
62
, have shown that diabetic patients are 
prone for increase in LDL and total cholesterol than other lipid abnormalities. 
This finding of dyslipidemia play an important role increasing the risk of 
developing cardiovascular risk the study also echoed the need of incorporating 
serum lipid profile as routine investigation to minimize complications. 
dyslipidemia and therefore cardiovascular risk. 
Christos Kalofoutis et al
63
 have shown that type 2 diabetes, metabolic 
syndrome, and insulin resistance are associated with cardiovascular mortality 
and morbidity. Targeting multiple cardiovascular risk factors offers best CVD 
outcome and. He also demonstrated low grade inflammation exists in these 
individuals leading to atherosclerosis. 
               Joanna Pollak et al
64
 studies evidenced that microalbuminuria is 
associated with cardiovascular events and mortality. So screening for 
microalbuminuria with the sensitive and reliable methods available has clinical 
importance as that of blood pressure and lipid profile. 
            Seema Basi et al
65 
study had concluded that the presence of 
albuminuria, a powerful predictor of cardiovascular risk in diabetes and 
hypertensive individuals. Reducing the level of albuminuria  decreases  risk of 
cardiovascular and renal outcomes. 
              The study done by Gerstein et al
66
 have shown that microalbuminuria 
is an independent risk factor for cardiovascular events like cardiac failure and a 
cause of mortality in people with previous history of CHF. 
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          King et al
67
have shown that CRP levels are increased in non diabetics 
with insulin resistance, in type 2 diabetes, and in type 1 diabetic individuals. 
Obesity rather than hyperglycemia contributes to elevated CRP levels.  A 
proinflammatory state prevails in the prediabetics, 5 years before the actual 
onset of diabetes. This contributes to atherosclerosis and cardiovascular risk. 
             Desouza et al
68
studies concluded even the hypoglycemia occurring 
during the strict control of diabetes leads to the inflammatory activation and 
increase in counter regulatory hormones leading to macrovascular 
complications. 
          Pedicino et al
69
 studies have shown that immunity and inflammation 
plays a key role in the pathogenesis of atherosclerosis and its complications. 
Immune responses in endothelial activation, plaque development, and rupture, 
as demonstrated by the increased levels of inflammatory markers or certain 
lymphocyte population and the risk of occurrence of cardiovascular morbidity 
and mortality. 
          Schultz et al
70
have demonstrated in his studies that BMI have an effect 
in the development of cardiovascular events. This association was subsequently 
confirmed in 2 separate cohorts of women. These findings provide evidence 
that the association between dietary factors and risk of 2 diabetes may be 
mediated  in part by inflammation and endothelial  dysfunction. 
 
 
 
  
 
MATERIALS 
AND METHODS 
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MATERIALS AND METHODS 
Study design: 
               It is a cross sectional study. 
 
Place of study: 
             The study was conducted in Tirunelveli medical college hospital, 
Tirunelveli. 
 
Collaborating department: 
         Department of Medicine, Tirunelveli medical college, Tirunelveli. 
         Department of Biochemistry, Tirunelveli medical college, Tirunelveli. 
   Department of Pathology, Tirunelveli medical college, Tirunelveli. 
 
Period of study: 
           6 months (December 2014-may 2015). 
 
Study subjects: 
          200   diabetic individual  (age 35-55 years), both men and women. 
 
Inclusion criteria: 
About 200 type 2 diabetic individuals of both men and women between  
 35-55 years were included. 
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Exclusion criteria: 
 Type 1 diabetic individuals 
 Known malignant disease 
  After vigorous exercise 
 History of heart failure 
 Urinary tract infection 
  Liver cirrhosis 
 Haematological diseases 
  Advanced renal dysfunction(serum creatinine >2.0mg/dl) 
 Those taking medications like steroid and anti allergy agents. 
 
Materials used for the study: 
1. Proforma : To obtain detailed history, to record the anthropometric 
measurements of  subjects, and  clinical findings. 
2.  To detect Microalbuminuria from early morning urine sample using Semi 
auto analyser (Model : chem5x from Erba manheim ).  
3.  To find Total Leucocyte count, differential count evaluated using semi 
autoanalyser (Model: Sysmex KX-21,Transasia Sr.No.KX-B8608 from 
Erba Manheim) 
4. Fasting Blood Glucose using Semi auto analyser (Model: Chem5x from 
Erba Manheim). 
5. HbA1 C using Semi auto analyser (Model: Chem5x from Erba Manheim). 
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6. Lipid profile done using full auto analyser (Model:Multi XL V2014.03B 
 EM 360 from Erba Maheim) 
7. ECG was taken (Model: EDAN SE-1) machine. 
 
METHODOLOGY 
The study was initiated with the approval of Institutional ethical 
committee. The study was carried out after explaining the procedures in detail 
and getting written informed consent from all the subjects.  
Measurement of blood pressure 
Blood pressure was measured using mercury sphygmomanometer after 
30 minutes of rest (Pickering et al., 2005). Blood pressure ≥140/90 mmHg 
was considered as hypertensives. 
Measurement of anthropometric indices: 
Height: 
Using stadiometer vertical height was measured in centimetres to the 
nearest 0.5 centimetres. 
Weight: 
Weight in kilograms was recorded using a portable standard weighing         
machine. 
 
Body mass index: 
        Body mass index was calculated using the Quetlet’s formula.  
 
MEASUREMENT OF WAIST CIRCUMFERENCE 
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BMI =weight (kg)/height (m2). Individuals with BMI ≥ 25(obese) were taken 
for the study. 
 
 
 
 
 
 
Waist circumference: 
Waist circumference was measured using a nonelastic measuring tape. 
Reading was taken in the horizontal plane, midway between the inferior margin 
of the ribs and the superior border of the iliac crest, at the level of umbilicus.  
Increased waist circumference was >80 cm (women), >90 cm (men). 
Blood investigations 
Under strict aseptic precautions, blood samples were collected from 
antecubital vein using 5 ml disposable syringes. Out of that, 3ml was put in the 
centrifuge tube and allowed to clot for 15 minutes then it was centrifuged for 
approximately 10 minutes at a centrifugal force of 1000 x g to 2000 x g  and 
separated the serum in plain tube for biochemical tests. Remaining 2ml was put 
in EDTA tube, the blood was mixed gently and used for hematological tests.  
 
 
 
BMI(Kg/m²) Classification 
18.5-22.9 Normal 
 23.0-24.9 Overweight 
 25.0-29.9 Obese 
TAKING BLOOD SAMPLE 
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Haematological test 
Total leucocyte count and differential count were found out using 
semiauto analyser. 
Results were interpreted as follows:
71
 
 
Types of cell 
Normal 
count(cells/mm
3
) 
Percent(%) 
Total leucocyte count 4000-11000 100 
Neutrophils 2000-7000 50-70 
Eosinophils 50-500 1-4 
Lymphocytes 1500-4000 20-40 
monocytes 200-800 2-8 
 
 
Total leucocyte count >7400 cells/mm
3
 is considered as high normal for the 
study. 
 
 
 
 
 
  
 
 
SEMI AUTO ANALYSER 
(TOTAL LEUCOCYTE COUNT MEASUREMENT) 
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Biochemical tests: 
Lipid profile: 
Total cholesterol and triglycerides were determined using Standard 
enzymatic methods. HDL-C was measured by direct assay method. VLDL was 
calculated by dividing triglycerides by 5, and LDL was calculated by taking 
the difference of total Cholesterol and VLDL. 
 
 Results interpreted as follows 
72
 
   
                                LIPID PROFILE 
 
Fasting blood sugar: 
Subject was instructed not to eat or drink except water for 10-12 hours 
and the early morning blood samples were taken. Normal fasting blood sugar 
is <126mg/dl according to ADA
73
.So values ≥ 126mg/dl was considered for 
the study. 
 
 
 
PARAMETERS NORMAL 
VALUES(mg/dl) 
INCREASED(mg/dl) 
Total cholesterol 150 -250 >200 
Triglycerides <150 >150 
LDL <100 >100 
 
HDL 
MEN <40 >40 
WOMEN <50 >50 
FULL AUTO ANALYSER 
(LIPID PROFILE) 
 
SEMI AUTO ANALYSER 
(MICRO ALBUMINURIA) 
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HbA1C 
HbA1C was measured by photoelectric colorimeter model XSYSOO54. 
Normal value is< 6.5%
74
. So values ≥ 6.5% was considered high for the 
study.   
Microalbuminuria: 
The first morning urine sample was collected in disposable containers 
from diabetic patients.  Microalbuminuria was measured by using semi-   
quantitative auto analyser using reagent. 
Normal value of albumin excretion   < 25 mg/litre 
Microalbuminuria                               ≥ 25-200 mg/litre 
Individuals with microalbuminuria level ≥  25-200 mg/litre was 
considered as microalbuminuria, and individuals with <25mg/litre was 
considered as normoalbuminuria. 
ECG: 
A resting 12 lead ECG was recorded in supine position with EDAN SE-
1 machine. These ECGs were read and coded on the basis of Minnesota code 
classification 4–1 or 4–2 or 5–1 or 5–2 or 6–1 or 6–2 or 7–1 or 7–2 or 8–1 or 
8–3 and interpreted as present or absent.75  
           All the collected data were tabulated for individual cases in the form of 
master chart for 200 volunteers included in the study and they were divided 
into two groups. Albumin excretion ≥ 25-200mg/l as microalbuminuria 
group and albumin excretion < 25mg/l as normoalbuminuria group. 
 
RECORDING ECG 
 
 
 
  
 
RESULT 
ANALYSIS 
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RESULTS 
 
STATISTICAL ANALYSIS 
 
This information collected regarding all the selected subjects were 
recorded in a Master Chart. When the data was analysed it was found that 66 
diabetic individuals had microalbuminuria, 55 individuals had increased Total 
leucocyte count and 48 individuals had changes in ECG out of 200 subjects.  
 
All the data were analysed using SPSS Software Version 11.  
 
Using this software range, frequencies, percentage, means standard 
deviations, chi square and „p‟ values were calculated. Data analysed using 
unpaired t test. Correlation was calculated using Spearman rho Correlation. 
P value was used to assess the significance. P value < .05 was considered more 
significant. 
 
Microsoft excel was used to create charts, graphs and tables.  
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TABLE 1 
  INCIDENCE OF MICROALBUMINURIA AMONG STUDY GROUP                                      
 Microalbuminuria 
(≥ 25-200 mg/l) 
% Normoalbuminuria 
(< 25 mg/l) 
% Total 
Male 34 17 70 35 104 
Female 32 16 64 32 96 
Total 66 33 134 67 200 
  
Incidence of microalbuminuria among study group was 33%. 
 
                                   
 
 
17%
16%
35%
32%
Incidence
Microalbuminuria  male
Microalbuminuria  female
Normoalbuminuria male
Normoalbuminuria  female
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TABLE 2 
 
CORRELATION BETWEEN MICROALBUMINURIA AND BMI                     
  
 
 Correlation coefficient P value 
BMI 0.195 0.006* 
* Highly Significant  
 There is significant correlation between microalbuminuria and BMI. 
  BMI is increased in microalbuminuria group.  
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28.5
microalbuminuria group Normoalbuminuria group
BMI
microalbuminuria group
Normoalbuminuria groupB
M
I K
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2
           Group                BMI P value 
Mean SD 
Microalbuminuria 
 (≥ 25-200 mg/l) 
27.92 3.93 < .0001 
Highly significant 
Normoalbuminuria (< 25 mg/l) 25.79 3.05 
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TABLE 3 
CORRELATION BETWEEN MICROALBUMINURIA AND WAIST 
CIRCUMFERENCE 
 
 
 Correlation coefficient P value 
Waist Circumference 0.186 0.008* 
* Highly Significant  
 
 There is positive correlation between microalbuminuria and waist 
circumference.  
  Waist circumference is increased in microalbuminuria group  .   
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           Group Waist circumference P value 
Mean SD 
Microalbuminuria 
 (≥ 25-200 mg/l) 
 95.02 6.72 0.002* 
Normoalbuminuria (< 25 mg/l) 92.0 5.87 
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TABLE 4 
ASSOCIATION BETWEEN MICROALBUMINURIA AND BP 
 
 
 Correlation coefficient P value 
SBP 0.485 <0.0001* 
DBP 0.515 <0.0001* 
* Highly Significant  
 
 There is highly significant correlation between microalbuminuria , 
systolic  as well as diastolic BP.  
 Systolic and diastolic BP increased in microalbuminuria group. 
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           Group SYSTOLIC BP DIASTOLIC BP 
Mean SD mean SD 
Microalbuminuria 
 (≥ 25-200 mg/l) 
138.12 12.9 91.52 9.77 
normoalbuminuria (< 25 mg/l) 121.37 16.72 76.313 11.66 
P VALUE <0.0001 
Highly significant 
<0.0001 
Highly significant 
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TABLE 5 
CORRELATION BETWEEN MICROALBUMINURIA, TLC, DC 
*HIGHLY SIGNIFICANT 
 
 Correlation coefficient P value 
Total leucocyte count 0.563 <0.0001* 
Neutrophils 0.462 <0.0001* 
Eosinophils -0.067 0.348 
Lymphocytes -0.475 <0.0001* 
Monocytes 0.073 0.304 
* Highly Significant  
 
 There is highly significant positive correlation between 
microalbuminuria , total leucocyte count and neutrophils 
 .There is no correlation between microalbuminuria and eosinophil count. 
 There is significant negative correlation between microalbuminuria and 
lymphocyte count. Individuals with positive microalbuminuria had 
decreased lymphocyte count. 
 There is correlation between microalbuminuria and monocyte count, but 
not significant.  
 
 Microalbuminuria             
(≥ 25 -200mg/l) 
Normoalbuminuria               
(< 25 mg/l) 
P VALUE 
Mean SD Mean SD 
TLC 8596.97 1677.08 5625 1398.8 <0.0001* 
NEUTROPHILS 68.01 9.47 61.32 7.57 <0.0001* 
EOSINOPHILS 3.95 2.97 4.46 4.46 0.404 
LYMPHOCYTES 18.72 6.80 28.29 8.64 <0.0001* 
MONOCYTE 8.13 4.15 6.59 2.72 0.002 
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CORRELATION BETWEEN MICROALBUMINURIA, TLC, DC 
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TABLE 6 
   CORRELATION BETWEEN MICROALBUMINURIA AND LIPID PROFILE 
 
 Correlation coefficient P value 
T.Cholesterol 0.023 0.744 
Triglycerides 0.368 <0.0001* 
LDL 0.237 0.001* 
HDL -0.316 <0.0001 
* Highly Significant  
 There is no significant association between microalbuminuria and total 
cholesterol. 
 Significant correlation exists between microalbuminuria and 
triglycerides. 
 Correlation between microalbuminuria and LDL level is not significant. 
 There is significant correlation between microalbuminuria and HDL 
level. 
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Microalbuminuria  group Normoalbuminuria group
total cholesterol(mg/dl)
triglycerides(mg/dl)
LDL(mg/dl)
HDL(mg/dl)
(m
g
/d
l)
    Microalbuminuria             
(≥ 25 -200mg/l) 
Normoalbuminuria               
(< 25 mg/l) 
P 
VALUE 
Mean SD Mean SD 
Total cholesterol 190.11 41.54 179.01 27.75 0.025 
Triglycerides 190.61 30.95 156.96 29.73 <.0001* 
LDL 99.74 8.84 96.91 12.99 0.112 
HDL 43.17 5.33 47.72 5.40 <.0001* 
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TABLE 7 
ASSOCIATION BETWEEN MICROALBUMINURIA AND FBS 
 
 Correlation coefficient P value 
FBS 0.478 <0.0001* 
* Highly Significant  
 There is highly significant correlation between microalbuminuria and 
FBS. 
   FBS is above normal among the individuals in microalbuminuria 
group. 
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Group FBS P value 
Mean SD 
Microalbuminuria 
 (≥ 25-200 mg/l) 
137.74 43.36 < .0001 
Highly significant 
Normoalbuminuria (< 25 mg/l) 99.06 18.76 
71 
 
TABLE 8 
 
ASSOCIATION  BETWEEN MICROALBUMINURIA AND HbA 1C 
 
 Correlation coefficient P value 
HbA1c 0.576 <0.0001* 
* Highly Significant  
 
 There is highly significant correlation between microalbuminuria and 
HbA1C. 
  HbA1C value is increased   in  microalbuminuria group . 
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microalbuminuria group
Normoalbuminuria group
%
           Group          HbA1C P value 
Mean SD 
Microalbuminuria 
(≥25-200mg/l) 
7.86 0.86 < .0001 
Highly significant 
Normoalbuminuria(<25mg/l) 6.35 0.82 
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TABLE 9 
ECG CHANGES IN THE STUDY GROUP 
ECG 
CHANGES 
 Microalbuminuria 
(25-200mg/l)       
Normoalbuminuria 
(<25mg/l) 
TOTAL 
 
No.of.persons 
 
 
% 
 
No.of.persons 
 
% 
PRESENT 29 15 11 6 40 
ABSENT 37 19 123 62 160 
TOTAL 66 34 134 68 200 
 
 Correlation coefficient P value 
ECG 0.334 <0.0001* 
* Highly Significant  
 
 More number of persons in Normoalbuminuria group had no changes in 
ECG. 
 
 
 
19%
15%
62%
ECG CHANGES
microalbuminuria group,no 
ECG changes
Microalbuminuria group,with 
ECG changes
Normoalbuminuria ,without 
ECG changes
Normoalbuminuria,with ECG 
changes
6%
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TABLE 10 
RELATION BETWEEN MICROALBUMINURIA AND       SMOKING   
HISTORY 
 
 There is no significant correlation between microalbuminuria and 
smoking 
 But more non smokers are normoalbuminuric. 
 Correlation coefficient P value 
SMOKING 0.080 0.261  
 
 
 
21%
12%
48%
19%
SMOKING HISTORY
Microalbuminuria 
group, smoking history absent
Microalbuminuria 
group, smoking history 
present
Normoalbuminuria, smoking 
history absent
Normoalbuminuria,smoking 
history present
SMOKING 
HISTORY 
Microalbuminuria  
(≥25-200mg/l) 
 
Normoalbuminuria 
(<25mg/l) 
TOTAL 
No.of.person 
 
 
 
% 
No.of.persons  
% 
PRESENT 24 12 38 19 72 
ABSENT 42 21 96 48 138 
TOTAL 66 33 134 67 200 
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TABLE 11 
COMPARISON  OF PREVALENCE OF MICROALBUMINURIA, 
LEUCOCYTE COUNT, BMI, HBA1C, AND POSITIVE ECG CHANGES 
IN RELATION WITH DURATION OF DIABETES. 
Duration 
(years) 
Persons  
N=200  
Microalbu
minuria  
 (≥ 25-200 
mg/l) 
N=66 
TLC > 
7400 
Cells/ 
mm
3 
(N=55) 
BMI 
≥ 25 
N=42 
HbA1C 
> 6.5 % 
N=78 
ECG 
changes 
present 
N=48 
5 55 (27.5%) 13 (19.7%) 11 (20%) 9 (21.4%) 18(23%) 4(8.3%) 
6 45 (22.5%) 10 (15.2%) 6 (10.9%) 5 (11.9%) 13(16.7%) 3(6.3%) 
7 41 (20.5%) 12 (18.2%) 
13 
(23.6%) 
10 (23.8%) 12(15.4%) 6(12.5%) 
8 40 (20%) 17 (27.8%) 
16 
(29.1%) 
8 (19%) 21(26.9%) 15(31.3%) 
>8 19 (9.5%) 13 (19.7%) 9 (16.4%) 10 (23.8%) 14(17.9%) 10(20.8%) 
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DISCUSSION 
Investigations to find a suitable biomarker for inflammatory process in 
type 2 diabetes and its association with the complications have been underway 
for many years. Numerous biomarkers have been investigated. In this study we 
have investigated whether total leucocyte count can be added to diabetes 
control protocol as an early bedside routine investigation. Inflammatory 
process of the whole system can be reflected by total leucocyte count and this 
study was conducted to correlate the total leucocyte count, differential count, 
microalbuminuria and cardiovascular risk in type 2 diabetes mellitus. 
The prevalence of microalbuminuria in type 2 DM in our study was 
33%, which was similar to the study done by Ahmedani et al 
76
 at Karachi 
which was about 34%.  In another study done by Nevi Pasko et al 
77
in Tirana, 
the prevalence was 38%.The greater prevalence of microalbuminuria in the 
study done by Nevi Pasko et al may be due to greater duration of diabetes in 
patients selected. In our study there was no significant difference in the 
prevalence of microalbuminuria in both sexes. 
Our study showed that patients with microalbuminuria group had higher 
BMI, and increased waist circumference. The mechanism responsible for this 
is that the adipose tissue not only act as an energy storage but also act as an 
endocrine organ and release various adipocytokines causing  endothelial 
change  leading to microalbuminuria. 
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  In our study individuals with microalbuminuria had elevated systolic as 
well as diastolic blood pressure. This could be due to the endothelial 
dysfunction produced by microalbuminuria and causing development of 
atherosclerosis. 
 In our study, we found that patients with microalbuminuria had elevated 
total leucocyte count. This was due to activation of leucocytes by advanced 
glycation end products, oxidative stress and angiotensinII by hyperglycemia 
which produce changes in the endothelium resulting in microvascular 
complications. This result was similar to the study done by Zaiden et 
al
78
which showed that, elevated leucocyte count even though found in the 
normal range may have an effect on development of microalbuminuria. This 
might be due to activation of inflammatory process associated with diabetes. 
   In this study, microalbuminuria group with elevated leucocyte count 
had more ECG changes indicating the atherosclerotic changes produced by 
prolonged inflammation in the coronary vessels. Chung et al 
79
 found that 
peripheral WBC‟s, monocytes and neutrophil count increased in patients with 
the advancement of diabetic nephropathy. And the elevation in leucocyte count 
was associated with both micro and macrovascular complications, in diabetic 
individuals with microalbuminuria. 
 In another cross sectional study in 2004 by Chan et al
80
 on 3776 
Chinese diabetic patients in Hong Kong, it was  demonstrated that higher 
leucocyte count even though in the normal range was independently related to 
both microvascular  and macrovascular  complications of diabetes and this  
78 
 
study also found a direct relationship between  leucocyte count , BMI, and 
HbA1C.  
When differential count was considered in this study, microalbuminuria 
individuals had elevated neutrophil count, but not other counts especially 
lymphocyte count was in negative range. The mechanisms for this could be 
due to neutrophil influx from marrow storage and decreasing efflux from the 
blood stream. 
 Another theory is that neutrophil production is stimulated in bone 
marrow by low insulin levels in blood. The immune system of diabetic patients 
contains some receptors that induce inflammation in the blood vessels. In 
addition to other risk factors, chronic inflammatory responses can lead to 
diabetes complications by inducing massive endothelial injury and increase in 
some mediators. Bjornson et al; collier et al 
81
both had quoted similar 
mechanisms in their study. 
Leptin secretion from adipocytes is also increased by cortisol and insulin 
resistance and this leptin might be involved in increased leucocyte count by 
stimulating myeloid differentiation from human bone marrow 
CD34progenitors and can induce proliferation, differentiation, functional 
activation of hemopoietic cells as shown in studies done by Gainsford et al
82
 
        The study done by Hanson et al
83   
have shown that inflammation plays a 
key role in atherosclerosis and coronary heart disease. Immune cells dominate 
early atherosclerotic lesions and lead to progression of the lesions and 
activation of inflammation lead to acute coronary syndromes. 
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             Another study conducted in Turin University on 659 Italian patients 
by cavalot et al
84
 showed that in patients with diabetes WBC count correlated 
with albumin excretion rate, one of the marker of subclinical inflammation 
associated with both insulin resistance and atherosclerosis. 
In our study also there was a positive correlation between duration of 
diabetes, control of diabetes and cardiac changes. Madjid et al
85
had also 
demonstrated a correlation between leucocyte count and ischemic heart 
disease. Possible mechanisms include endothelial injury by proteolytic 
enzymes, vessel plugging, decreased perfusion, abnormal leucocyte 
aggregation, electrical instability, increased thrombus formation, increased 
leucocyte adhesion in coronary artery disease. 
 Jafar et al
86
 studies associated microalbuminuria positive individuals 
had more ECG changes and therefore had higher cardiovascular risk.  
               In the previous studies incidence of coronary heart disease was 1.9 
fold higher with WBC counts >7000cells/mm³ than in those with counts <4800 
cells/mm³.Twig et al
87
 study on Israeli army personnel states that with WBC 
counts >7000cells/mm³ had twice incidence of coronary heart disease as those 
with WBC count <5000cellsmm³. 
  Yutaka Takeda et al 
88
 had concluded in his studies that elevated WBC 
count even in normal range is associated with acute coronary syndrome. It was 
also suggested that elevated WBC count does not reflect acute inflammatory 
process but a chronic inflammation responsible for plaque vulnerability. 
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                 Our study results showed that individuals with history of smoking 
had elevated total leucocyte count, microalbuminuria, triglycerides and ECG 
changes. This might be due to the activation of immune system and 
inflammatory processes leading to the endothelial dysfunction and 
atherosclerosis.  
Chong do lee et al
89
 had supported our finding and he had demonstrated 
a dose response relationship between WBC count and cardiovascular disease 
mortality persisted for cigarette smoking. 
Giuseppe schillaci et al
90
 had a positive correlation with body weight, 
systolic blood pressure, cigarette smoking, fasting blood sugar, fasting insulin 
level and negative correlation with HDL , family income, alcohol 
consumption, physical activity or physical fitness. 
 In our study we had elevated fasting blood sugar and HbA1C in 
microalbuminuria individuals and this was due to uncontrolled diabetes 
causing elevated HbA1C and endothelial damage by advanced glycation end 
products. 
. 
.    
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SUMMARY AND CONCLUSION 
 Diabetic individuals had a greater risk of developing both 
microvascular and macrovascular complications. Mortality due to 
diabetes is mainly because of cardiovascular abnormalities and 
cerebrovascular accidents. So if individuals prone for developing 
these complications are detected at an earlier date, it is possible to 
take necessary precautions to control the same. For that we need a 
simple and cost effective lab investigation that is done routinely. 
 A correlation between total leucocyte count, differential count 
microalbuminuria and cardiovascular risk factors and ECG changes 
were investigated in 200 diabetic individuals. 
 Multivariate analysis was done  
 And it was found that 66 individuals had microalbuminuria, 54 had 
increased total leucocyte count and 48 had ECG changes. 
 Smoking, positive family history of diabetes, increased BMI and 
increased waist circumference had elevated total leucocyte count, 
microalbuminuria, increased triglycerides, and increased blood 
pressure. 
 Individuals with increased fasting blood sugar, HbA1C had elevated 
total leucocyte count, microalbuminuria and ECG changes.   
 The results showed statistical significance. 
 
82 
 
 To conclude, since there exists a correlation between total leucocyte 
count, microalbuminuria and cardiovascular risk, total leucocyte 
count can also be used as a simple and cost effective method  to detect 
the microvascular and macrovascular complications earlier thereby 
reducing  the mortality and morbidity associated with diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FUTURE SCOPE 
OF STUDY 
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FUTURE SCOPE OF THE STUDY 
 In the future we can involve a large number of subjects 
(>1000) including both male and female.  
  We can also include acute phase reactants like C-reactive 
protein and fibrinogen to exclude acute infections. 
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ANNEXURES 
 
 
 
CORRELATION  BETWEEN  LEUCOCYTE  COUNT, 
MICROALBUMINURIA AND CARDIOVASCULAR  RISK  IN  TYPE 2  
DIABETES MELLITUS 
                             
PROFORMA 
 
Sl.no       :                                                        Income     : 
                                                                         Address   : 
Date       :   
Name     : 
Age         : 
Sex         : 
Personal history 
1. Dietary history    :  Veg / Non-veg 
2. Sleep duration    :      hrs.    Regular / Iregular 
3. Physical activity:   Yes / No 
4. Smoking history :   Yes / No 
5. Intake of alcohol :Yes / No 
6. History of diabetes: Yes / No ,if yes   duration : 
7. History of hypertension: Yes / No ,if yes   duration : 
8.Family history of DM/HT/CAD/stroke : Yes / No 
8. History of cardiac illness : Yes / No 
9.Any other complaints     : 
 
 
CLINICAL EXAMINATION 
 Temperature    :                                                              Pulse  :        /min                              
BP         :               mm Hg                                                RR  :       /min 
CVS  :                                                
RS      : 
ANTHROPOMETRIC MEASUREMENTS: 
Height   :                cm        Weight :                  kg    BMI:                  kg/m² 
Waist circumference :                        cm 
HAEMATOLOGICAL PARAMETERS: 
 Total leucocyte count                    Cells/mm³ 
Neutrophil count                    Cells/mm
3
 
Eosinophil count                   Cells/mm
3
 
Lymphocyte  count                    Cells/mm
3
 
Monocyte count                    Cells/mm
3
 
 
BIO-CHEMICAL MEASUREMENTS: 
Parameters values 
Blood cholesterol (mg/dl)  
Triglycerides  (mg/dl)  
LDL   (mg/dl)  
HDL  (mg/dl)  
Fasting Blood sugar  (mg/dl)  
 
ECG     : 
 
 
CONSENT : I hereby give my volunteer consent for the above study 
 
 
                                                                                                                 Signature                                          
CONSENT FORM 
 
Dr. M. PRADEEPA, Post graduate student in the department of physiology, 
Tirunelveli Medical College, Tirunelveli is studying  the Correlation between 
total Leucocyte count, Microalbuminuria and Cardiovascular risk in type2 
diabetes mellitus-a cross sectional study. The test procedures are 
1. Blood investigation (Total Leucocyte Count, Lipid Profile, 
HbA1C, FBS) 
2. Urine investigation (Microalbuminuria) 
3. ECG 
4. BP Measurement  
5. Waist Measurement  
The procedure was explained to me clearly. I understand that there are no risks 
involved in the above procedures. I hereby give my consent to participate in the 
study. The data obtained may be used for research and other publication 
purpose.  
 
Name: 
Place: 
Signature: 
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1 Ponnuthai 49 F A 6 A 140 55 28.1 86 100 70 6100 4148 122 1525 305 172 140 150 55 89 5.8 1.1 A
2 Kavitha 40 F A 5 P 145 50 23.8 90 120 70 4800 3264 96 1200 240 168 140 94 45 90 6.8 1.3 A
3 Mathavan 52 M A 7 P 165 60 22 90 120 70 5900 3658 177 1593 472 215 180 91 42 98 5.8 1.5 A
4 Syedalibeevi 37 F A 7 A 160 55 21.5 80 110 70 5800 3712 116 1856 188 170 135 94 55 84 6.2 2 A
5 Solaiappan 50 M A 5 P 162 70 26.7 98 140 86 4800 2976 96 1824 134 140 150 94 52 90 6.2 2.3 A
6 Shanaz 53 F A 6 A 155 65 27.1 96 100 70 4800 3264 240 720 576 160 155 95 48 86 8.2 2.4 A
7 Sasikala 51 F A 7 A 145 52 24.7 95 100 10 5500 3025 275 1870 330 220 145 99 48 83 5.8 2.4 A
8 Sathappan 38 M A 2 A 155 55 22.9 92 130 80 5300 3498 212 1166 424 180 180 102 40 94 6.5 2.4 A
9 Raman 57 M A 6 A 162 75 28.6 98 120 80 5700 3306 220 2052 114 190 145 96 46 140 6.2 2.4 P
10 Mariammal 52 F A 5 P 150 48 21.3 80 116 90 4500 2790 225 1260 225 186 130 96 55 96 6.2 2.8 A
11 Paruthi 45 F A 6 A 152 60 26 90 130 86 6700 3886 469 1675 670 195 186 93 48 120 5.8 2.8 A
12 Kaveri 52 F A 6 P 148 45 20.5 83 120 72 4800 2640 1680 480 240 170 100 82 54 84 6.4 3.2 A
13 Antoniammal 52 F A 8 A 145 62 29.5 98 110 70 4300 2322 172 1462 344 195 154 94 45 89 5.8 3.2 A
14 Poongothai 45 F A 5 A 148 50 22.8 88 110 60 4800 2592 240 1728 240 180 150 89 40 89 7 3.2 P
15 Kayani 46 F A 8 A 162 70 26.7 92 120 70 5300 3127 265 1378 530 205 195 90 46 97 4.8 3.3 A
16 Vijayasankar 48 M A 8 A 175 80 26.1 92 130 70 5300 2862 318 1590 530 150 200 94 53 98 5.8 3.5 A
17 Andal 48 F A 7 A 162 70 26.7 89 120 70 6200 3472 558 1550 558 180 215 98 52 96 5.8 4.2 A
18 K.Shanthi 45 F A 7 A 150 45 24.4 81 100 60 4900 3332 98 1225 342 152 145 96 49 100 5.6 4.3 A
19 Rajan 42 M P 7 P 155 60 25 98 120 80 4800 2928 96 1488 288 200 185 90 42 98 6.2 4.3 A
20 Shankar 51 M P 8 A 160 70 27.3 98 130 80 4800 3024 240 624 528 180 145 85 42 98 4.1 4.4 A
21 Kandhi 48 M A 6 P 170 78 27 96 130 60 4900 2940 147 1470 343 150 130 90 48 96 6.4 4.5 A
22 Nagarajan 48 M P 5 A 152 62 26.8 96 120 86 6200 4340 310 1240 310 185 185 99 45 96 6.8 4.8 P
23 Mahalakshmi 45 F A 6 A 155 60 25 88 110 70 5300 2915 159 1908 318 215 142 94 52 96 6.2 4.9 A
24 Pappammal 55 F A 5 A 145 52 24.7 95 100 60 10100 7070 202 2525 303 250 146 94 50 124 6.8 5 A
25 Saraswathy 52 F A 5 A 148 60 27.4 88 130 90 15200 12008 1620 912 760 252 180 98 42 130 8.2 5 A
26 Pockia selavn 43 M A 7 A 168 65 26.4 98 100 80 4300 2666 172 1290 172 188 140 100 50 86 5.3 5.2 A
27 Deivarani 45 F A 5 P 150 65 28.9 101 120 70 4800 3168 192 1152 288 180 140 104 51 92 6.2 5.7 A
28 Janaki 49 F A 8 A 152 64 27.7 94 120 86 5300 2756 212 1908 424 185 130 100 50 78 5.4 5.8 A
29 Sudalai 48 M P 6 A 158 78 31.2 94 130 76 4500 2520 90 1485 405 212 245 90 42 105 6.5 5.8 A
30 Ponnammal 50 F A 5 A 160 58 22.7 82 130 80 4800 3360 96 1200 144 185 100 80 50 82 5.2 6 A
31 Ritta 55 M A 10 P 162 54 30.1 90 130 80 4400 2640 88 1320 352 170 135 92 50 98 6.4 6 P
32 Kavitha 48 F A 8 A 148 80 36.5 94 110 86 4900 2891 147 1519 343 165 145 94 40 96 5.9 6.2 A
33 Saraswathy 48 F A 5 P 150 60 25.3 84 90 60 5100 2805 255 1734 306 160 155 196 54 86 6.3 6.4 A
34 Sankarammal 51 F A 6 A 150 55 24.4 80 116 70 6300 4032 252 1512 504 180 142 90 52 88 6.8 7 A
35 Malar 47 F A 7 A 145 50 23.8 86 110 80 5500 2860 220 1980 440 165 165 98 55 94 6.4 7.2 A
36 Kumar 50 M P 6 A 170 78 27 92 130 80 5800 3712 232 1392 464 145 145 94 42 98 6.4 7.3 P
37 Pauldurai 55 M P 10 A 156 70 28.8 86 100 60 6900 4416 276 2001 345 160 215 102 50 88 6.1 7.3 P
38 Senthil 46 M P 8 P 165 72 26.4 104 150 70 4200 2310 126 1512 252 215 142 99 45 96 6.5 7.5 A
39 kadarali 39 M A 5 P 165 68 23 94 110 70 5400 3024 216 1782 378 186 135 94 55 80 6.5 7.8 A
40 Kalangium 52 F A 5 A 160 54 21.1 98 120 80 5200 3224 364 1196 416 215 144 95 52 98 6.2 8 P
41 Parvathy 40 F A 5 A 142 52 25.8 84 120 70 6300 3969 252 1764 315 180 145 89 48 85 6.2 8 A
42 Mohammad 35 M P 2 A 168 80 25 101 120 70 8000 4640 320 2400 640 185 145 92 53 85 6.8 8 A
43 Ismayil 50 M P 5 A 148 52 23.7 94 120 80 5800 3944 116 1624 116 160 140 100 55 85 6.8 8 A
44 Meenakshi 48 F A 8 A 142 55 27.3 88 150 90 4800 2880 144 1152 624 185 205 95 38 90 6.2 8.1 A
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45 Ajmer 47 M P 9 A 152 60 26 94 140 96 5200 2808 312 1716 364 125 194 98 43 80 7.4 8.1 A
46 Hari 45 M P 5 A 160 72 28.1 90 110 80 5300 3127 265 1643 265 195 145 85 45 105 5.4 8.1 A
47 Kannan 54 M P 7 A 164 80 29.7 94 150 110 9200 6440 184 2760 736 150 185 100 45 160 6.2 8.1 A
48 Baseera 50 F A 5 A 148 62 28.3 98 160 100 5800 3596 174 1856 174 152 140 102 50 140 6.2 8.2 A
49 Saratha 46 F A 8 A 156 65 26.7 92 110 80 5300 3392 159 689 1060 150 175 105 40 120 9.2 8.2 A
50 Kannan 52 M P 5 P 168 82 29.1 102 120 80 5300 3180 212 1749 318 205 145 114 42 88 6.3 8.2 A
51 Romasubhu 43 M A 5 A 168 72 25.5 96 120 70 8200 5904 164 2296 328 215 182 96 38 122 8.2 8.4 A
52 Vasan 52 M P 8 A 170 80 27.7 101 140 100 6300 3528 315 2079 567 186 155 96 48 95 7 8.8 A
53 Lakshmi 50 F A 6 A 152 62 26.8 82 120 80 5800 4988 174 1392 406 182 140 92 52 106 6.6 9 A
54 Kamatchi 54 F A 6 P 148 60 27.4 98 120 80 4900 3234 196 1176 294 184 140 96 43 92 6.5 9 A
55 Ponprasad 45 M A 5 A 165 60 22 95 132 80 4200 2268 210 1470 210 184 140 96 45 70 6.8 9 A
56 Bharathi 48 F A 7 A 155 70 29.1 98 110 76 4800 2592 144 1728 336 220 185 101 52 94 5.9 9.1 A
57 Kuruvammal 54 F A 8 A 168 75 26.6 86 110 70 5100 3468 102 1224 306 140 140 95 51 101 6.2 9.2 A
58 Fathimuthu 55 F A 7 A 150 60 26.7 82 110 70 5300 3498 212 1272 318 155 135 94 52 92 6.3 9.2 A
59 Arafed 40 M P 5 A 145 50 23.8 90 130 70 5800 3364 174 1914 348 185 215 94 40 96 5.8 9.2 A
60 Kumaravel 51 M P 8 P 160 65 25.4 110 130 80 5300 2915 159 1908 318 215 142 95 42 160 6.5 9.3 A
61 Saravanan 46 M P 6 P 165 73 26.8 90 120 60 4200 2310 126 1512 252 215 142 90 45 96 6.2 9.3 A
62 Ponmuthu 52 F A 8 A 148 60 27.4 88 140 80 5800 3016 290 1972 522 192 136 94 48 95 5.3 9.4 A
63 Vani 42 F A 6 P 158 65 26 94 100 70 4800 2592 528 1152 528 145 215 92 48 94 8.8 9.4 A
64 Malayammal 50 F A 6 A 154 55 23.2 89 120 82 5800 3132 348 1740 580 186 142 80 53 92 5.6 10 A
65 Chelliah 54 M P 7 A 158 50 20 92 120 70 5500 3025 825 1375 275 190 150 96 45 88 5 10 A
66 Pooranam 49 F A 6 A 145 50 23.8 86 100 60 5500 3740 110 1430 220 184 135 94 50 82 5.8 10.15 A
67 Sathapan 43 M P 5 P 162 65 24.8 91 130 80 5400 3348 162 1728 162 124 140 110 53 96 6.5 10.2 A
68 Karuppan 52 M A 5 A 168 58 23 101 13.8 82 5300 3498 106 1378 318 200 142 101 43 85 5.5 11 A
69 Pappa 39 F A 5 A 145 50 23.8 88 120 70 4800 2880 240 1344 336 140 190 94 42 115 6.2 11.3 A
70 Mookandi 40 M P 5 A 168 75 20 101 130 88 6100 3782 183 1708 427 180 140 106 52 85 6.5 11.3 A
71 Karuppian 49 M P 6 P 155 62 25.8 94 130 90 6900 4002 276 2070 552 160 155 98 50 94 5.2 11.3 A
72 Rajasekar 52 M P 7 A 158 62 24.8 94 120 70 4300 2494 172 1290 344 145 125 82 50 99 3.1 11.3 A
73 Pari 48 M P 6 A 155 60 25 90 130 90 5400 3132 216 1620 432 145 185 101 44 112 6.8 11.3 A
74 Muthukmar 52 M P 7 A 155 60 25 105 110 70 8300 4814 332 2490 664 180 215 102 50 98 6.2 11.4 A
75 Poominathan 54 M P 8 A 168 90 31.9 92 140 90 4800 2784 192 1440 384 180 225 101 40 96 8.1 11.4 A
76 Selvi 48 F A 6 P 145 50 23.8 90 120 70 4700 2726 188 1410 376 145 190 92 35 140 5.6 11.8 A
77 Rajeswari 42 F A 5 A 155 62 25.8 82 100 80 6200 3596 248 1860 496 180 145 92 52 96 5.3 12.2 A
78 Ibrahim 50 M A 8 P 150 60 26.7 94 130 90 5400 3132 216 1620 432 213 140 90 50 96 7.8 12.3 A
79 Saraswathy 46 F A 6 A 169 70 24.5 92 140 90 5700 3306 228 1710 456 215 138 98 52 98 7.2 12.4 A
80 Mahesh 50 M A 5 P 155 80 33.3 104 130 70 4800 2784 192 1440 384 215 142 106 45 125 8.1 12.4 A
81 Sevugan 51 M P 8 P 159 65 25.7 94 150 90 5300 3074 212 1590 424 176 160 104 52 99 6.6 12.4 A
82 Senthamarai 50 F A 7 P 153 80 34.2 86 130 86 4800 2784 192 1440 384 180 215 90 40 84 5.8 12.5 A
83 Shermakani 59 F A 8 A 142 45 22.3 89 110 70 5300 3074 212 1590 424 155 130 94 52 88 6.2 12.9 A
84 Geetha 48 F A 6 A 158 68 27.2 88 130 60 4300 2494 172 1290 344 220 140 94 55 145 6.8 13 A
85 Alexandar 47 M A 7 A 160 55 28.3 92 130 70 6200 3596 248 1860 496 180 140 94 45 90 7.3 13 A
86 Mathiyarasi 50 F A 8 A 140 55 28.1 98 110 70 5400 3132 216 1620 432 135 195 97 40 96 6.5 13.1 A
87 Murugan 50 M P 7 A 170 63 21.8 90 120 80 4800 2784 192 1440 384 145 142 115 42 85 6.8 13.1 A
88 Valliammal 54 F A 5 A 155 50 20.8 88 130 70 4300 2494 172 1290 344 180 135 85 55 90 6.5 14 A
89 Kasilakshmi 45 F A 5 P 152 56 24.2 88 110 70 4300 2494 172 1290 344 155 125 92 55 80 5.5 14 A
90 Mohammed rafi 52 M A 6 A 170 75 26 94 130 80 8000 4640 320 2400 640 150 294 94 45 148 7.4 14 A
91 Michael 53 M A 5 A 154 75 31.6 92 100 60 5300 3074 212 1590 424 124 140 105 48 96 6.8 14 A
92 Selvalakshmi 42 F A 5 P 140 50 25.5 85 110 70 5500 3190 220 1650 440 155 170 90 55 94 5.8 14.2 A
93 Abbas 52 M P 8 P 155 60 25 90 140 90 4800 2784 192 1440 384 170 155 105 52 98 6.8 14.2 A
94 Kamal 48 M P 5 A 168 70 26.7 98 102 84 6200 3596 248 1860 496 150 130 101 42 96 6.4 14.3 A
95 Chinnakannan 52 M P 7 P 160 82 32 96 120 86 5400 3132 216 1620 432 165 175 96 42 96 5.3 14.4 A
96 Shanmugathai 54 F A 5 A 140 45 23 80 110 70 4500 2610 180 1350 360 182 140 92 50 9.2 6.5 15 P
97 Devadran 45 M A 5 A 163 66 24.8 94 130 88 6400 3712 256 1920 512 185 156 92 50 90 5.5 15 A
98 Lakshmanan 49 M A 5 A 175 78 25.5 92 130 70 5500 3190 220 1650 440 184 198 90 54 92 6.8 15.2 A
99 Paulsamy 41 M A 5 A 172 65 22 96 140 80 5300 3074 212 1590 424 190 145 94 45 102 5.8 15.2 A
100 Rajamohan 50 M P 8 A 155 60 22.7 93 130 80 4800 2784 192 1440 384 188 142 94 40 94 6.8 15.2 A
101 Valli 46 F A 6 A 140 52 26.5 90 100 60 6800 3944 272 2040 544 140 150 89 52 90 5.6 15.3 A
102 Sundari 42 F A 5 A 146 48 21.9 86 116 76 4800 2784 192 1440 384 250 156 96 52 80 6.5 16 P
103 Sundari 46 F A 6 A 156 52 21.1 83 100 60 6200 3596 248 1860 496 186 140 82 52 78 5 16 A
104 Valliammal 50 F A 5 P 158 55 22 82 130 80 5100 2958 204 1530 408 175 180 101 40 105 6.4 16 A
105 Retina raja 48 M P 5 A 159 65 25.7 94 130 70 5300 3074 212 1590 424 186 142 94 44 86 6.3 16 A
106 Deepa 48 F A 4 A 160 58 22.7 92 100 60 4500 2610 180 1350 360 165 125 94 52 88 6.6 16.1 A
107 Mareeswari 52 F A 9 A 142 60 29.8 96 120 80 5900 3422 236 1770 472 145 205 99 50 89 6.5 16.1 A
108 Gomathy 54 F A 6 A 152 45 19.5 85 140 80 5800 3364 232 1740 464 182 195 52 52 112 6.8 16.2 A
109 Chitra 38 F A 5 P 148 60 27.4 86 140 90 4800 2784 192 1440 384 186 145 96 58 116 6.5 16.2 A
110 Muthu 45 M P 6 A 150 55 24.4 92 150 100 6300 3654 252 1890 504 182 160 102 50 130 6.2 16.4 A
111 Ramachandran 52 M A 10 A 175 76 24.8 91 140 90 4800 2784 192 1440 384 185 100 97 52 117 6.4 17 A
112 Vijaya 45 F A 7 A 155 60 25 84 120 80 4300 2494 172 1290 344 145 185 88 30 120 7.9 17.1 A
113 Arivalagan 52 M A 8 P 162 68 25.9 101 130 80 4800 2784 192 1440 384 185 146 98 34 92 6.4 17.2 A
114 Thevendran 52 M A 6 A 163 60 22.6 100 120 86 7200 4176 288 2160 576 260 182 95 52 126 6.2 17.5 A
115 Angelin 50 F A 7 A 152 65 28.1 95 130 70 4700 2726 188 1410 376 110 180 98 40 110 6.2 18 A
116  Vembu mariappan 46 M A 6 A 152 50 21.6 92 130 70 7200 4176 288 2160 576 216 142 101 52 105 6.2 18 A
117 Sundarajan 50 M P 6 P 164 72 26.8 94 110 70 6500 3770 260 1950 520 215 138 102 45 98 6.8 18.1 A
118 Avudaiappan 53 M P 5 A 158 75 30 96 110 70 5100 2958 204 1530 408 220 135 96 58 82 5.4 18.1 A
119 Malathy 49 F A 6 A 162 68 25.7 88 106 58 4800 2784 192 1440 384 180 180 100 50 92 6.4 18.2 A
120 Saraswathy 44 F A 6 A 158 66 31.1 84 110 70 5100 2958 204 1530 408 175 130 98 52 80 6.2 18.2 A
121 Senguvan 48 M A 6 A 175 68 22.8 90 130 70 4800 2784 192 1440 384 152 140 120 51 86 7.2 18.2 A
122 Balachandran 50 M A 5 A 165 70 25.7 94 140 90 7200 4176 288 2160 576 195 154 145 48 125 6.4 18.2 A
123 Franklin 52 M A 6 P 155 75 31.2 95 120 80 4800 2784 192 1440 384 220 140 104 48 125 6.3 19.1 A
124 Sankar 55 M A 8 A 172 76 25.5 94 140 90 9200 5336 368 2760 736 196 135 89 40 132 6.5 19.3 P
125 Devandran 48 M P 8 P 152 60 26 92 140 80 6500 3770 260 1950 520 182 145 99 52 116 7.8 20 A
126 Kuppusamy 55 M P 10 A 170 82 28.4 98 130 80 9200 5336 368 2760 736 190 140 94 50 95 5 20 P
127 Balasubramanian 51 M A 6 A 155 55 22.9 92 130 70 4700 2726 188 1410 376 180 140 98 42 94 6.5 20 A
128 Suresh 42 M P 6 P 155 63 20.6 97 120 70 6700 3886 268 2010 536 180 140 94 40 102 6.7 20 A
129 Joseph 54 M A 7 A 145 60 28.5 96 104 80 4300 2494 172 1290 344 186 145 99 46 130 6.2 20.2 A
130 Valliammal 54 F A 7 A 155 60 25 88 140 80 4300 2494 172 1290 344 104 112 98 54 94 6.6 22 A
131 Petchmuthu 53 F A 8 A 142 55 27.3 88 110 80 8100 4698 324 2430 648 180 152 102 50 110 7.1 22 A
132 Francis 52 M A 7 A 162 82 31.2 102 150 100 4800 2784 192 1440 384 173 140 96 45 89 5.8 22 A
133 Lakshmi 46 F A 6 P 144 54 26 88 118 70 5100 2958 204 1530 408 185 200 80 52 114 6.8 23.1 A
134 Siddha Serhmam 48 M A 9 P 162 60 22.9 94 130 70 7100 4118 284 2130 568 150 185 93 50 120 6.8 23.2 A
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135 Sujatha 48 F A 7 P 145 65 30.9 90 150 90 7400 4884 518 1332 666 225 186 94 45 186 6.2 25.2 A
136 Premkumar 54 M P 9 A 166 72 26.1 88 150 100 9400 6204 658 1692 846 250 150 95 36 250 5.8 26.8 A
137 Subbiah 52 M P 9 A 164 70 26 98 140 90 10700 7062 749 1926 963 205 245 103 42 272 8.4 27.7 P
138 Marithai 45 F A 5 P 150 70 31.1 105 140 100 8800 5808 616 1584 792 189 215 82 45 125 8.4 29 A
139 Sudalai 52 M P 12 P 168 92 32.6 105 150 100 7500 4950 525 1350 675 208 208 105 36 138 9.2 29.3 A
140 Ramaiah 53 M A 8 A 158 80 26.6 100 140 96 8300 5478 581 1494 747 225 182 109 50 128 7.2 30 P
141 Vellammal 42 F A 5 P 160 75 29.3 91 140 110 11000 7260 770 1980 990 200 200 108 45 126 8.2 31.5 A
142 Jospbine 55 F A 6 P 145 55 26.2 90 130 90 7900 5214 553 1422 711 190 230 98 52 116 8.1 32 A
143 Pandaram 52 M P 7 A 158 65 26 94 140 90 8300 5478 581 1494 747 250 186 92 46 125 7.8 32 P
144 Umamaheswari 53 F A 7 A 145 70 33.3 102 130 100 8500 5610 595 1530 765 178 185 102 45 136 7.8 32.1 A
145 Sankari 52 F A 8 A 140 50 25.5 89 110 70 10200 6732 714 1836 918 215 170 94 50 135 8.2 32.6 A
146 Mariammal 45 F A 7 P 152 60 26 85 130 90 10000 6600 700 1800 900 163 106 104 48 130 8 33 A
147 velayutham 44 M P 8 P 160 75 29.3 92 120 70 7800 5148 546 1404 702 225 185 98 45 125 7.5 34.1 P
148 Arunothaya 55 F A 8 P 151 60 26.3 95 140 90 5700 3762 399 1026 513 286 180 92 42 130 8.1 34.7 P
149 Subbiah 45 M A 5 P 163 80 25 94 150 90 8200 5412 574 1476 738 215 185 108 42 122 7.4 35 A
150 Mary 48 F A 6 P 152 70 30.3 99 150 90 8200 5412 574 1476 738 154 185 98 40 125 7.4 36.5 P
151 Sindhu 50 F A 7 P 159 62 24.5 98 150 100 8600 5676 602 1548 774 145 185 88 40 125 7.8 36.5 P
152 Rengammal 45 F A 6 P 154 50 21.1 84 100 70 7800 5148 546 1404 702 190 120 95 56 90 5 38 A
153 Balkees 47 F A 8 P 156 66 27.1 88 170 90 9300 6138 651 1674 837 216 186 99 45 122 7.9 40 A
154 Arunachalam 48 M P 6 P 162 70 26.7 105 140 110 10300 6798 721 1854 927 152 190 105 40 130 7.9 40.2 A
155 Puthumani 55 M A 6 P 150 65 28.9 94 150 100 6300 4158 441 1134 567 215 245 98 42 135 6.2 40.2 A
156 Udaiyappan 50 M P 7 A 168 80 28.3 102 140 90 7500 4950 525 1350 675 185 215 98 34 180 8.4 40.3 P
157 Subbulakshmi 52 F A 6 A 148 58 26.5 92 130 90 6300 4158 441 1134 567 176 203 96 50 125 7.4 42 A
158 Gurunathan 53 M P 8 P 168 75 26.6 96 150 100 12000 7920 840 2160 1080 145 200 105 40 198 7.8 42.1 P
159 Arasi 52 F A 7 A 152 68 29.4 90 150 90 8200 5412 574 1476 738 154 185 92 40 125 6.2 42.4 A
160 Subbiah 42 M P 6 P 150 54 24 92 130 86 7400 4884 518 1332 666 190 146 86 45 80 8 42.5 A
161 Munigeswar 54 F A 9 A 140 75 38.3 101 140 100 10200 6732 714 1836 918 146 205 94 42 240 7.8 42.8 P
162 Ravi 53 M P 9 P 165 80 29.4 101 150 90 7800 5148 546 1404 702 180 215 105 40 152 7.8 43.2 P
163 Velumani 54 M P 8 A 150 65 28.9 102 130 90 8200 5412 574 1476 738 140 152 98 40 98 7.2 43.2 P
164 Mahesh 50 M A 5 P 155 55 22.9 94 130 96 9500 6270 665 1710 855 235 180 98 48 126 9.1 43.4 A
165 Parvathy 55 F A 8 P 150 65 28.9 88 150 100 8600 5676 602 1548 774 180 215 92 45 140 8.5 45.1 P
166 Ramanan 55 M P 5 A 170 90 31.1 101 130 80 8200 5412 574 1476 738 185 245 115 38 250 9.4 45.4 P
167 Kulamani 45 F A 5 P 160 62 24.2 90 150 96 12400 8184 868 2232 1116 145 185 96 48 126 7.9 47.8 A
168 Chinnammal 54 F A 5 P 152 60 26 84 120 70 8300 5478 581 1494 747 135 140 96 52 96 6.8 48 P
169 Mupidathi 48 F A 8 A 148 62 28.3 88 140 96 9900 6534 693 1782 891 190 235 130 42 126 9 50.3 A
170 Muthumanikam 39 M P 4 A 162 58 22.1 94 100 70 6100 4026 427 1098 549 160 185 94 50 92 6.2 51 A
171 Fatima 53 F A 9 P 158 85 34 92 130 90 8500 5610 595 1530 765 160 205 120 38 145 8.8 52.1 P
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172 Puthiyavan 51 M A 7 P 164 82 30.5 96 150 110 9200 6072 644 1656 828 150 185 94 42 160 9 52.4 P
173 Vethamani 50 M A 7 P 160 52 32 92 130 90 8500 5610 595 1530 765 184 140 110 42 90 7.8 53.9 A
174 alangaram 48 M P 7 P 158 90 36.1 105 150 100 9200 6072 644 1656 828 145 185 108 34 215 9.1 54.2 P
175 Ramu 55 M P 15 P 160 90 35.2 98 130 90 9400 6204 658 1692 846 160 160 100 40 150 8.3 58.5 A
176 Ulagammal 54 F A 5 A 148 60 27.4 90 130 90 8100 5346 567 1458 729 140 182 96 51 90 8.1 59 A
177 Syed ali 52 M P 7 P 152 59 25.5 98 130 80 9200 6072 644 1656 828 250 180 106 40 128 7.3 59 A
178 Gomathi 53 F A 8 A 145 50 23.8 94 120 70 7500 4950 525 1350 675 125 185 100 54 105 8.2 60.1 P
179 Sankarammal 52 F A 6 P 152 68 29.4 84 150 90 9100 6006 637 1638 819 220 180 90 42 115 7.5 62 A
180 Mariappan. G 45 M P 8 P 170 100 34.6 100 140 90 8300 5478 581 1494 747 140 140 97 38 140 8.1 62.4 A
181 Sanharalingam 52 M P 5 P 160 70 27.3 105 140 90 10200 6732 714 1836 918 270 190 96 39 128 8.5 62.6 P
182 Mariappan 45 M P 8 P 172 90 30.4 100 140 90 11000 7260 770 1980 990 152 184 102 40 280 8.1 65 P
183 Sekar 50 M P 9 P 168 90 31.9 108 140 90 8300 5478 581 1494 747 212 245 102 50 180 8.8 66.8 A
184 Lakshmi 50 F A 8 A 145 60 28.5 101 130 90 4300 2838 301 774 387 255 160 101 45 116 8 69 A
185 Francis 55 M A 5 P 165 56 20.6 92 110 70 5900 3894 413 1062 531 155 180 104 52 116 6.8 69 A
186 Kumar 43 M P 8 A 155 62 22 98 130 90 8300 5478 581 1494 747 168 215 98 38 135 8.1 70 P
187 Ramya 55 F A 6 A 145 50 23.8 94 160 90 5500 3630 385 990 495 150 215 92 42 120 8.1 70.2 A
188 Dhasammal 55 F A 10 P 148 62 28.3 95 140 90 5700 3762 399 1026 513 280 162 105 48 86 8.2 73 P
189 Santha 42 F A 5 P 165 60 22 82 150 110 8500 5610 595 1530 765 205 180 80 35 128 8.2 75 A
190 Bathirakali 46 F A 7 P 145 60 28.5 95 130 90 10500 6930 735 1890 945 300 285 85 50 120 8.2 78 P
191 Kabilan 55 M A 9 A 165 80 29.4 98 140 90 7800 5148 546 1404 702 180 215 92 35 152 6.2 80.2 A
192 Parvathy 50 F A 5 P 162 75 28.6 98 130 90 11000 7260 770 1980 990 185 215 101 42 135 8 86 A
193 Vellammal 50 F A 6 P 155 48 21.5 82 150 90 5300 3498 371 954 477 180 180 98 40 82 7.5 88.5 A
194 Gomathi 55 F A 8 A 150 70 31.1 84 140 100 8500 5610 595 1530 765 180 220 103 38 128 7.6 91 A
195 Subbiah 54 M P 8 P 165 59 21.7 94 150 100 8000 5280 560 1440 720 285 180 105 40 130 8.3 97 P
196 Raju 55 M P 12 P 158 86 29 98 150 100 12800 8448 896 2304 1152 146 183 96 48 124 9.1 98 P
197 kandasamy 40 M A 5 P 168 86 30.5 98 140 100 9200 6072 644 1656 828 180 210 110 42 80 7.8 99 A
198 Kalangium 52 F A 8 P 153 60 25.6 84 140 100 9000 5940 630 1620 810 180 225 116 46 130 8.1 107 P
199 Ramalingam 55 M P 10 P 130 62 36.2 105 136 90 9500 6270 665 1710 855 184 182 94 32 128 8.5 120 P
200 Ramlinga periumal 55 M A 10 P 150 70 23.8 110 150 100 10300 6798 721 1854 927 184 182 120 40 130 8.3 129 P
N - Neutrophils
E - Eosinophils
L - Lyphocytes
M - Monocytes
FBS - Fasting Blood Sugar
LDL - Low Density Lipoprotein
HDL- High Density Lipoprotein
ECG- Electro Cardiogram Changes
A- Absent
P - Present
